<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Rofecoxib</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Rofecoxib">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Rofecoxib</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Rofecoxib</b> is a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). It was marketed by Merck &amp; Co. to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, acute pain conditions, migraine, and dysmenorrhea. Rofecoxib was approved in the US by the US Food and Drug Administration (FDA) in May 1999, and was marketed under the brand names Vioxx, Ceoxx, and Ceeoxx. Rofecoxib was available by prescription in both tablet-form and as an oral suspension.<span class="mw-ref" id="cite_ref-1"><a href="#cite_note-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>


<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Rofecoxib</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Rofecoxib.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Rofecoxib.svg.png" data-file-width="224" data-file-height="251" data-file-type="drawing" height="157" width="140"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Rofecoxib-3D.png" tppabs="https://ptable.com/wiki/compounds/I/m/Rofecoxib-3D.png" data-file-width="736" data-file-height="476" data-file-type="bitmap" height="91" width="140"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pronunciation</th><td><span class="rt-commentedText nowrap"><span class="IPA nopopups noexcerpt">/<span style="border-bottom:1px dotted"><span>ˌ</span><span>r</span><span>ɒ</span><span>f</span><span>ɪ</span><span>ˈ</span><span>k</span><span>ɒ</span><span>k</span><span>s</span><span>ɪ</span><span>b</span></span>/</span></span><span> </span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Vioxx, Ceoxx, Ceeoxx, others</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>C<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>oral &amp; i.m</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>M01AH02<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=M01AH02  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=M01AH02'" tppabs="https://www.whocc.no/atc_ddd_index/?code=M01AH02" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li>withdrawn  worldwide</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>93%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>87%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>hepatic</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>17 hours</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>biliary/renal</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=162011-90-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=162011-90-7'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=162011-90-7" class="external text external">162011-90-7</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/5090  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/5090'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/5090" class="external text external">5090</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2893  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2893'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2893" class="external text external">2893</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00533  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00533'" tppabs="https://www.drugbank.ca/drugs/DB00533" class="external text external">DB00533</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.4911.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.4911.html'" tppabs="http://www.chemspider.com/Chemical-Structure.4911.html" class="external text external">4911</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=0QTW8Z7MCR  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=0QTW8Z7MCR'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=0QTW8Z7MCR" class="external text external">0QTW8Z7MCR</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D00568  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D00568'" tppabs="https://www.kegg.jp/entry/D00568" class="external text external">D00568</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8887  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8887'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8887" class="external text external">CHEBI:8887</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL122  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL122'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL122" class="external text external">ChEMBL122</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID2023567  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID2023567'" tppabs="https://comptox.epa.gov/dashboard/DTXSID2023567" class="external text external">DTXSID2023567</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.230.077  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.230.077'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.230.077" class="external text external">100.230.077</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>17</sub><span>H</span><sub>14</sub><span>O</span><sub>4</sub><span>S</span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">314.36</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC2OCC%28%3DC2%5Cc1ccccc1%29%5Cc3ccc%28cc3%29S%28%3DO%29%28%3DO%29C  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC2OCC%28%3DC2%5Cc1ccccc1%29%5Cc3ccc%28cc3%29S%28%3DO%29%28%3DO%29C'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC2OCC%28%3DC2%5Cc1ccccc1%29%5Cc3ccc%28cc3%29S%28%3DO%29%28%3DO%29C" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">O=C2OCC(=C2\c1ccccc1)\c3ccc(cc3)S(=O)(=O)C</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:RZJQGNCSTQAWON-UHFFFAOYSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=470623576&page2=Rofecoxib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=470623576&page2=Rofecoxib'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=470623576&page2=Rofecoxib" class="external text external">(verify)</a></span></span></td></tr></tbody></table>
<p>Rofecoxib gained widespread use among physicians treating patients with arthritis and other conditions causing chronic or acute pain. Worldwide, over 80 million people were prescribed rofecoxib at some time.<span class="mw-ref" id="cite_ref-NPR_Merck_2004_2-0"><a href="#cite_note-NPR_Merck_2004-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>

<p>In September 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use. Merck withdrew the drug after disclosures that it withheld information about rofecoxib's risks from doctors and patients for over five years, allegedly resulting in between 88,000 and 140,000 cases of serious heart disease.<span class="mw-ref" id="cite_ref-3"><a href="#cite_note-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Rofecoxib was one of the most widely used drugs ever to be withdrawn from the market. In the year before withdrawal, Merck had sales revenue of US$2.5 billion from Vioxx.<span class="mw-ref" id="cite_ref-4"><a href="#cite_note-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>

<p>In 2005 the FDA issued a memo concluding that data from large long-term controlled clinical trials do not clearly demonstrate that COX-2 selective agents (including rofecoxib) have a greater risk of serious CV events than non-selective NSAIDs.<span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> The FDA reinforced this position in 2015, stating that the available data support a dose and duration dependent class effect of an increased risk of serious adverse cardiovascular events for COX-2 selective and non-selective NSAIDs.<span class="mw-ref" id="cite_ref-fda.gov_6-0"><a href="#cite_note-fda.gov-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>

<p>In November 2017, Massachusetts-based Tremeau Pharmaceuticals announced its plan to return rofecoxib (TRM-201) to market as a treatment for hemophilic arthropathy (HA). Tremeau announced that the FDA had granted an orphan designation for TRM-201 (rofecoxib) for the treatment of HA, and that they had received FDA feedback on their development plan.<span class="mw-ref" id="cite_ref-Tremeau_Pharmaceuticals_News_7-0"><a href="#cite_note-Tremeau_Pharmaceuticals_News-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> HA is a degenerative joint disease caused by recurrent intra-articular bleeding. It is the largest cause of morbidity in patients with hemophilia and has no currently approved treatment options in the United States. Traditional NSAIDs are avoided in this population due to their effects on platelet aggregation and risk of gastrointestinal ulcers,<span class="mw-ref" id="cite_ref-Srivastava_e1–e47_8-0"><a href="#cite_note-Srivastava_e1–e47-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> and high potency opioids are the current standard of care in treating HA.<span class="mw-ref" id="cite_ref-Forsyth_1549_9-0"><a href="#cite_note-Forsyth_1549-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>
<style data-mw-deduplicate="TemplateStyles:r886046785">.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}</style><div class="toclimit-3"><meta property="mw:PageProp/toc"></div>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mode_of_action">Mode of action</h2></summary>
    

<p>Cyclooxygenase (COX) has two well-studied isoforms, called COX-1 and COX-2. COX-1 mediates the synthesis of prostaglandins responsible for protection of the stomach lining, while COX-2 mediates the synthesis of prostaglandins responsible for pain and inflammation. By creating "selective" NSAIDs that inhibit COX-2, but not COX-1, the same pain relief as traditional NSAIDs is offered, but with greatly reduced risk of fatal or debilitating peptic ulcers. Rofecoxib is a selective COX-2 inhibitor, or "coxib".</p>

<p>Though the class of coxibs includes several agents, there are varying degrees of COX-2 selectivity among them, with celecoxib (Celebrex) being the least COX-2 selective, and rofecoxib (Vioxx), valdecoxib (Bextra), and etoricoxib (Arcoxia), being highly COX-2 selective.<span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>

<p>At the time of its withdrawal, rofecoxib was the only coxib approved in the United States with clinical evidence of its superior gastrointestinal adverse effect profile over conventional NSAIDs. This was largely based on the VIGOR (Vioxx GI Outcomes Research) study, which compared the efficacy and adverse effect profiles of rofecoxib and <a href="Naproxen.htm" tppabs="https://ptable.com/wiki/compounds/A/Naproxen" title="Naproxen">naproxen</a>.<span class="mw-ref" id="cite_ref-Bombardier_2000_11-0"><a href="#cite_note-Bombardier_2000-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics">Pharmacokinetics</h3></summary>
    
<p>The therapeutic recommended dosages were 12.5, 25, and 50<span>&nbsp;</span>mg with an approximate bioavailability of 93%.<span class="mw-ref" id="cite_ref-Merck_12-0"><a href="#cite_note-Merck-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-Gold_13-0"><a href="#cite_note-Gold-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span><span class="mw-ref" id="cite_ref-Davies_14-0"><a href="#cite_note-Davies-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> Rofecoxib crossed the placenta and blood–brain barrier,<span class="mw-ref" id="cite_ref-Merck_12-1"><a href="#cite_note-Merck-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-Gold_13-1"><a href="#cite_note-Gold-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span><span class="mw-ref" id="cite_ref-Padi_15-0"><a href="#cite_note-Padi-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> and took 1–3 hours to reach peak plasma concentration with an effective half-life (based on steady-state levels) of approximately 17 hours.<span class="mw-ref" id="cite_ref-Merck_12-2"><a href="#cite_note-Merck-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-Davies_14-1"><a href="#cite_note-Davies-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-Scott_16-0"><a href="#cite_note-Scott-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> The metabolic products are cis-dihydro and trans-dihydro derivatives of rofecoxib<span class="mw-ref" id="cite_ref-Merck_12-3"><a href="#cite_note-Merck-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-Scott_16-1"><a href="#cite_note-Scott-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> which are primarily excreted through urine.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Efficacy">Efficacy</h2></summary>
    
<p>Rofecoxib was approved by the FDA to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, acute pain conditions, migraine, and dysmenorrhea. When it was marketed, it gained widespread acceptance among physicians treating patients with arthritis and other conditions causing chronic or acute pain.<span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Premenstrual_acne">Premenstrual acne</h3></summary>
    
<p>A 2003 placebo-controlled small short-term study in India of 80 women with premenstrual acne vulgaris acne, were given rofecoxib or placebo for 2 cycles of 10 days suggest that "rofecoxib is effective in the management of premenstrual acne.<span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Fabricated_efficacy_studies">Fabricated efficacy studies</h3></summary>
    
<p>On March 11, 2009, Scott S. Reuben, former chief of acute pain at Baystate Medical Center, Springfield, Mass., revealed that data for 21 studies he had authored for the efficacy of the drug (along with others such as <a href="Celecoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Celecoxib" title="Celecoxib">celecoxib</a>) had been fabricated, overstating the analgesic effects of the drugs. There is no evidence that Reuben colluded with Merck in falsifying his data. Reuben was also a former paid spokesperson for the drug company Pfizer (which owns the intellectual property rights for marketing celecoxib in the United States). The retracted studies were not submitted to either the FDA or the European Union's regulatory agencies prior to the drug's approval. Drug manufacturer Merck had no comment on the disclosure.<span class="mw-ref" id="cite_ref-WSJ-3-2009_19-0"><a href="#cite_note-WSJ-3-2009-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span><span class="mw-ref" id="cite_ref-WSJ_Mathews_2004_20-0"><a href="#cite_note-WSJ_Mathews_2004-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects">Side effects</h2></summary>
    

<div class="thumb tright"><div class="thumbinner" style="width:202px"><img src="../I/m/VIOXX_sample_blister_pack.jpg" tppabs="https://ptable.com/wiki/compounds/I/m/VIOXX_sample_blister_pack.jpg" data-file-width="1641" data-file-height="2227" data-file-type="bitmap" height="271" width="200"><div class="thumbcaption" style="text-align: left">A VIOXX (rofecoxib) sample blister pack.</div></div></div>

<p>In addition to the reduced incidence of gastric ulceration, rofecoxib exhibits no effect on bleeding time or platelet aggregation, even at supra-therapeutic doses.<span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> &nbsp;Aside from these features, rofecoxib exhibits a similar adverse effect profile to other NSAIDs.</p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Heart_and_blood_vessels">Heart and blood vessels</h3></summary>
    


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="VIGOR_study_and_publishing_controversy">VIGOR study and publishing controversy</h4></summary>
    
<p>The VIGOR (Vioxx GI Outcomes Research) study, conducted by Bombardier, et al., compared the efficacy and adverse effect profiles of a supra-therapeutic dose of rofecoxib (50<span>&nbsp;</span>mg/day) vs. a common dose of naproxen (500<span>&nbsp;</span>mg/BID), had indicated a significant 4-fold increased risk of acute myocardial infarction (heart attack) in rofecoxib patients when compared with <a href="Naproxen.htm" tppabs="https://ptable.com/wiki/compounds/A/Naproxen" title="Naproxen">naproxen</a> patients (0.4% vs 0.1%, RR 0.25) over a mean duration of 9-months. The elevated risk began during the second month on rofecoxib. There was no significant difference in the mortality from cardiovascular events between the two groups, nor was there any significant difference in the rate of myocardial infarction between the rofecoxib and naproxen treatment groups in patients without high cardiovascular risk. The difference in overall risk was by the patients at higher risk of heart attack, i.e. those meeting the criteria for low-dose aspirin prophylaxis of secondary cardiovascular events (previous myocardial infarction, angina, cerebrovascular accident, transient ischemic attack, or coronary artery bypass).<span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span></p>

<p>Merck's scientists interpreted the finding as a protective effect of naproxen, telling the FDA that the difference in heart attacks "is primarily due to" this protective effect.<span class="mw-ref" id="cite_ref-Cardio_23-0"><a href="#cite_note-Cardio-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> The Martin Report excused senior management by stating they believed they were victims of Pfizer's alleged manipulation of test results to promote their product as a safer alternative.<span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span> Some commentators have noted that naproxen would have to be three times as effective as <a href="Aspirin.htm" tppabs="https://ptable.com/wiki/compounds/A/Aspirin" title="Aspirin">aspirin</a> to account for all of the difference,<span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span> and some outside scientists warned Merck that this claim was implausible before VIGOR was published.<span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> No evidence has since emerged for such a large cardioprotective effect of naproxen, although a number of studies have found protective effects similar in size to those of aspirin.<span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span><span class="mw-ref" id="cite_ref-28"><a href="#cite_note-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span></p>

<p>The results of the VIGOR study were submitted to the United States Food and Drug Administration (FDA) in February 2001. In September 2001, the FDA sent a warning letter to the CEO of Merck, stating, "Your promotional campaign discounts the fact that in the VIGOR study, patients on Vioxx were observed to have a four to five fold increase in myocardial infarctions (MIs) compared to patients on the comparator non-steroidal anti-inflammatory drug (NSAID), Naprosyn (naproxen)."<span class="mw-ref" id="cite_ref-29"><a href="#cite_note-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span> This led to the introduction, in April 2002, of warnings on Vioxx labeling concerning the increased risk of cardiovascular events (heart attack and stroke).</p>

<p>Months after the preliminary version of VIGOR was published in the <i>New England Journal of Medicine in November 2000</i>, the journal editors learned that certain data reported to the FDA were not included in the <i>NEJM</i> article. Several years later, when they were shown a Merck memo during the depositions for the first federal Vioxx trial, they realized that these data had been available to the authors months before publication. The editors wrote an editorial accusing the authors of deliberately withholding the data.<span class="mw-ref" id="cite_ref-Curfman_2006a_30-0"><a href="#cite_note-Curfman_2006a-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span> They released the editorial to the media on December 8, 2005, before giving the authors a chance to respond. <i>NEJM</i> editor Gregory Curfman explained that the quick release was due to the imminent presentation of his deposition testimony, which he feared would be misinterpreted in the media. He had earlier denied any relationship between the timing of the editorial and the trial. Although his testimony was not actually used in the December trial, Curfman had testified well before the publication of the editorial.<span class="mw-ref" id="cite_ref-31"><a href="#cite_note-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span></p>

<p>The editors charged that "more than four months before the article was published, at least two of its authors were aware of critical data on an array of adverse cardiovascular events that were not included in the VIGOR article." These additional data included three additional heart attacks, and raised the relative risk of Vioxx from 4.25-fold to 5-fold. All the additional heart attacks occurred in the group at low risk of heart attack (the "aspirin not indicated" group) and the editors noted that the omission "resulted in the misleading conclusion that there was a difference in the risk of myocardial infarction between the aspirin indicated and aspirin not indicated groups." The relative risk for myocardial infarctions among the aspirin not indicated patients increased from 2.25 to 3 (although it remained statistically insignificant). The editors also noted a statistically significant (2-fold) increase in risk for serious thromboembolic events for this group, an outcome that Merck had not reported in the <i>NEJM</i>, though it had disclosed that information publicly in March 2000, eight months before publication.<span class="mw-ref" id="cite_ref-Curfman_2006b_32-0"><a href="#cite_note-Curfman_2006b-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>

<p>The authors of the study, including the non-Merck authors, responded by claiming that the three additional heart attacks had occurred after the prespecified cutoff date for data collection and thus were appropriately not included. (Utilizing the prespecified cutoff date also meant that an additional stroke in the naproxen population was not reported.) Furthermore, they said that the additional data did not qualitatively change any of the conclusions of the study, and the results of the full analyses were disclosed to the FDA and reflected on the Vioxx warning label. They further noted that all of the data in the "omitted" table were printed in the text of the article. The authors stood by the original article.<span class="mw-ref" id="cite_ref-33"><a href="#cite_note-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span></p>

<p><i>NEJM</i> stood by its editorial, noting that the cutoff date was never mentioned in the article, nor did the authors report that the cutoff for cardiovascular adverse events was before that for gastrointestinal adverse events. The different cutoffs increased the reported benefits of Vioxx (reduced stomach problems) relative to the risks (increased heart attacks).<span class="mw-ref" id="cite_ref-Curfman_2006b_32-1"><a href="#cite_note-Curfman_2006b-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>

<p>Some scientists have accused the <i>NEJM</i> editorial board of making unfounded accusations.<span class="mw-ref" id="cite_ref-34"><a href="#cite_note-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span><span class="mw-ref" id="cite_ref-35"><a href="#cite_note-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span> Others have applauded the editorial. Renowned research cardiologist Eric Topol,<span class="mw-ref" id="cite_ref-36"><a href="#cite_note-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span> a prominent Merck critic, accused Merck of "manipulation of data" and said "I think now the scientific misconduct trial is really fully backed up".<span class="mw-ref" id="cite_ref-37"><a href="#cite_note-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span> Phil Fontanarosa, executive editor of the prestigious <i>Journal of the American Medical Association</i>, welcomed the editorial, saying "this is another in the long list of recent examples that have generated real concerns about trust and confidence in industry-sponsored studies".<span class="mw-ref" id="cite_ref-38"><a href="#cite_note-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span></p>

<p>On May 15, 2006, the <i>Wall Street Journal</i> reported that a late night email, written by an outside public relations specialist and sent to <i>Journal</i> staffers hours before the Expression of Concern was released, predicted that "the rebuke would divert attention to Merck and induce the media to ignore the <i>New England Journal of Medicine</i><span class="nowrap" style="padding-left:0.1em;"><span>'</span></span>s own role in aiding Vioxx sales."<span class="mw-ref" id="cite_ref-WSJ515_39-0"><a href="#cite_note-WSJ515-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span></p>

<p>"Internal emails show the New England Journal's expression of concern was timed to divert attention from a deposition in which Executive Editor Gregory Curfman made potentially damaging admissions about the journal's handling of the Vioxx study. In the deposition, part of the Vioxx litigation, Dr. Curfman acknowledged that lax editing might have helped the authors make misleading claims in the article." The <i>Journal</i> stated that <i>NEJM</i><span class="nowrap" style="padding-left:0.1em;"><span>'</span></span>s "ambiguous" language misled reporters into incorrectly believing that Merck had deleted data regarding the three additional heart attacks, rather than a blank table that contained no statistical information; "the New England Journal says it didn't attempt to have these mistakes corrected."<span class="mw-ref" id="cite_ref-WSJ515_39-1"><a href="#cite_note-WSJ515-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> Investigations revealed that Merck had several years worth of information suggesting an elevated risk of cardiac events, and Vice President Edward Scolnick took much of the blame for the suppression of this information.<span class="mw-ref" id="cite_ref-40"><a href="#cite_note-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span><span class="mw-ref" id="cite_ref-41"><a href="#cite_note-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span><span class="mw-ref" id="cite_ref-42"><a href="#cite_note-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span></p>

<p>The FDA reviewers were aware of the potential for cardiovascular risk in 1999<span class="mw-ref" id="cite_ref-43"><a href="#cite_note-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span>and it was argued that Merck had manipulated their EKG tests one week after the external review board provided their consultation to specifically exclude high risk factors from the trial subjects to avoid finding effect then predated the changes to their trials to almost three months earlier.<span class="mw-ref" id="cite_ref-44"><a href="#cite_note-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Alzheimer's_disease">Alzheimer's disease</h4></summary>
    
<p>In 2000 and 2001, Merck conducted several studies of rofecoxib aimed at determining if the drug slowed the onset of Alzheimer's disease. Merck has placed great emphasis on these studies on the grounds that they are relatively large (almost 3000 patients) and compared rofecoxib to a placebo rather than to another pain reliever. These studies found an elevated death rate among rofecoxib patients, although the deaths were not generally heart-related. However, they did not find any elevated cardiovascular risk due to rofecoxib.<span class="mw-ref" id="cite_ref-45"><a href="#cite_note-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span> Before 2004, Merck cited these studies as providing evidence, contrary to VIGOR, of rofecoxib's safety.</p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="APPROVe_study">APPROVe study</h4></summary>
    
<p>In 2001, Merck commenced the APPROVe (Adenomatous Polyp PRevention On Vioxx) study, a three-year trial with the primary aim of evaluating the efficacy of rofecoxib for the prophylaxis of colorectal polyps. <a href="Celecoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Celecoxib" title="Celecoxib">Celecoxib</a> had already been approved for this indication, and it was hoped to add this to the indications for rofecoxib as well. An additional aim of the study was to further evaluate the cardiovascular safety of rofecoxib.</p>

<p>The APPROVe study was terminated early when the preliminary data from the study showed an increased relative risk of adverse thrombotic cardiovascular events (including heart attack and stroke), beginning after 18 months of rofecoxib therapy. In patients taking rofecoxib, versus placebo, the relative risk of these events was 1.92 (rofecoxib 1.50 events vs placebo 0.78 events per 100 patient years). The results from the first 18 months of the APPROVe study did not show an increased relative risk of adverse cardiovascular events. Moreover, overall and cardiovascular mortality rates were similar between the rofecoxib and placebo populations.<span class="mw-ref" id="cite_ref-Bresalier_2005_46-0"><a href="#cite_note-Bresalier_2005-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span></p>

<p>In summary, the APPROVe study suggested that long-term use of rofecoxib resulted in nearly twice the risk of suffering a heart attack or stroke compared to patients receiving a placebo.</p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Other_studies">Other studies</h4></summary>
    
<p>Pre-approval Phase III clinical trials, like the APPROVe study, showed no increased relative risk of adverse cardiovascular events for the first eighteen months of rofecoxib usage (Merck, 2004). Others have pointed out that "study 090," a pre-approval trial, showed a 3-fold increase in cardiovascular events compared to placebo, a 7-fold increase compared to nabumetone (another [NSAID]), and an 8-fold increase in heart attacks and strokes combined compared to both control groups.<span class="mw-ref" id="cite_ref-Cardio2_47-0"><a href="#cite_note-Cardio2-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span><span class="mw-ref" id="cite_ref-48"><a href="#cite_note-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span> Although this was a relatively small study and only the last result was statistically significant, critics have charged that this early finding should have prompted Merck to quickly conduct larger studies of rofecoxib's cardiovascular safety. Merck notes that it had already begun VIGOR at the time Study 090 was completed. Although VIGOR was primarily designed to demonstrate new uses for rofecoxib, it also collected data on adverse cardiovascular outcomes.</p>

<p>Several very large observational studies have also found elevated risk of heart attack from rofecoxib. For example, a recent retrospective study of 113,000 elderly Canadians suggested a borderline statistically significant increased relative risk of heart attacks of 1.24 from Vioxx usage, with a relative risk of 1.73 for higher-dose Vioxx usage. (Levesque, 2005). Another study, using Kaiser Permanente data, found a 1.47 relative risk for low-dose Vioxx usage and 3.58 for high-dose Vioxx usage compared to current use of celecoxib, though the smaller number was not statistically significant, and relative risk compared to other populations was not statistically significant. (Graham, 2005).</p>

<p>Furthermore, a more recent meta-study of 114 randomized trials with a total of 116,000+ participants, published in JAMA, showed that Vioxx uniquely increased risk of renal (kidney) disease, and heart arrhythmia.<span class="mw-ref" id="cite_ref-cox2drugreview.org_49-0"><a href="#cite_note-cox2drugreview.org-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Other_COX-2_inhibitors">Other COX-2 inhibitors</h4></summary>
    
<p>In 2005, the FDA issued a memo concluding that along with the other approved COX-2 selective NSAIDs available at the time (i.e., celecoxib, and valdecoxib), rofecoxib was associated with an increased risk of serious adverse CV events compared to placebo. They also noted that the available data did not permit a rank ordering of these drugs with regard to CV risk.<span class="mw-ref" id="cite_ref-50"><a href="#cite_note-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span></p>

<p>Only Celebrex (generic name is celecoxib) is still available for purchase in the United States.</p>

<p>Regulatory authorities worldwide now require warnings about cardiovascular risk of COX-2 inhibitors still on the market. For example, in 2005, EU regulators required the following changes to the product information and/or packaging of all COX-2 inhibitors:<span class="mw-ref" id="cite_ref-EMEA2005_51-0"><a href="#cite_note-EMEA2005-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span></p>

<ul><li>Contraindications stating that COX-2 inhibitors must not be used in patients with established ischaemic heart disease and/or cerebrovascular disease (stroke), and also in patients with peripheral arterial disease</li>
<li>Reinforced warnings to healthcare professionals to exercise caution when prescribing COX-2 inhibitors to patients with risk factors for heart disease, such as hypertension, hyperlipidaemia (high cholesterol levels), diabetes and smoking</li>
<li>Given the association between cardiovascular risk and exposure to COX-2 inhibitors, doctors are advised to use the lowest effective dose for the shortest possible duration of treatment</li></ul>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Other_NSAIDs">Other NSAIDs</h4></summary>
    
<p>Since the withdrawal of Vioxx it has come to light that there may be negative cardiovascular effects with not only other COX-2 inhibitiors, but even the majority of other NSAIDs. It is only with the recent development of drugs like Vioxx that drug companies have carried out the kind of well executed trials that could establish such effects and these sort of trials have never been carried out in older "trusted" NSAIDs such as <a href="Ibuprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibuprofen" title="Ibuprofen">ibuprofen</a>, <a href="Diclofenac.htm" tppabs="https://ptable.com/wiki/compounds/A/Diclofenac" title="Diclofenac">diclofenac</a> and others. The possible exceptions may be <a href="Aspirin.htm" tppabs="https://ptable.com/wiki/compounds/A/Aspirin" title="Aspirin">aspirin</a> and <a href="Naproxen.htm" tppabs="https://ptable.com/wiki/compounds/A/Naproxen" title="Naproxen">naproxen</a> due to their anti-platelet aggregation properties.</p>

<p>Analyses in 2011 and 2013 by McGettigan and the Coxib and traditional NSAID Trialists (CNT) Collaborators, respectively, demonstrated that the risk of serious CV events was a dose dependent effect of COX-2 selective and nonselective NSAIDs, with the possible exception of naproxen, and high therapeutic doses of nonselective NSAIDs (e.g. ibuprofen 2400<span>&nbsp;</span>mg/day, diclofenac 150<span>&nbsp;</span>mg/day) carried similar CV risk when compared to a combined group of therapeutic and supra-therapeutic doses of COX-2 selective&nbsp; NSAIDs (such as rofecoxib).<span class="mw-ref" id="cite_ref-52"><a href="#cite_note-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-53"><a href="#cite_note-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span></p>

<p>In 2014, Patrono and Baigent, summarizing all of the currently available data in a review article in Circulation, concluded that with the exception of GI toxicity, neither the efficacy nor the major cardiorenal complications of COX-2 selective NSAIDs appear to be influenced by their level of COX-2 selectivity. They concluded that the CV risk associated with NSAIDs was dependent on dose and duration.<span class="mw-ref" id="cite_ref-54"><a href="#cite_note-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span></p>

<p>This conclusion was further reinforced by the 2016 results of the celecoxib PRECISION trial, which showed no difference in CV event rates between the COX-2 selective NSAID celecoxib and the non-selective NSAIDs ibuprofen and naproxen.<span class="mw-ref" id="cite_ref-55"><a href="#cite_note-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Withdrawal">Withdrawal</h2></summary>
    
<p>Due to the findings of its own APPROVe study, Merck publicly announced its voluntary withdrawal of the drug from the market worldwide on September 30, 2004.<span class="mw-ref" id="cite_ref-56"><a href="#cite_note-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span><span class="mw-ref" id="cite_ref-NPR_2004_57-0"><a href="#cite_note-NPR_2004-57" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span></p>

<p>In addition to its own studies, on September 23, 2004, Merck apparently received information about new research by the FDA that supported previous findings of increased risk of heart attack among rofecoxib users (Grassley, 2004). One FDA analyst estimated that, based upon his mathematical model, Vioxx may have caused between 88,000 and 139,000 heart attacks, 30 to 40 percent of which were probably fatal, in the five years the drug was on the market. Senior FDA officials were quick to note, however, that this estimate was based solely on a mathematical model, and must be interpreted with caution.<span class="mw-ref" id="cite_ref-58"><a href="#cite_note-58" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span></p>

<p>On November 5, 2004, the medical journal <i>The Lancet</i> published a meta-analysis of the available studies on the safety of rofecoxib<span class="mw-ref" id="cite_ref-Jüni_2004_Lancet_59-0"><a href="#cite_note-Jüni_2004_Lancet-59" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span> (Jüni <i>et al.</i>, 2004). The authors concluded that, owing to the known cardiovascular risk, rofecoxib should have been withdrawn several years earlier. <i>The Lancet</i> published an editorial which condemned both Merck and the FDA for the continued availability of rofecoxib from 2000 until the recall.<span class="mw-ref" id="cite_ref-60"><a href="#cite_note-60" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></span><span class="mw-ref" id="cite_ref-Lancet_Implosion_Merck_2004_61-0"><a href="#cite_note-Lancet_Implosion_Merck_2004-61" style="counter-reset: mw-Ref 61;"><span class="mw-reflink-text">[61]</span></a></span> Merck responded by issuing a rebuttal of the Jüni <i>et al.</i> meta-analysis that noted that Jüni omitted several studies that showed no increased cardiovascular risk.<span class="mw-ref" id="cite_ref-62"><a href="#cite_note-62" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Merck-sponsored_&quot;Martin_Report&quot;,_2006">Merck-sponsored "Martin Report", 2006</h3></summary>
    

<p>In 2005, Merck spent $21 million US<span class="mw-ref" id="cite_ref-nothing_wrong_63-0"><a href="#cite_note-nothing_wrong-63" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></span> to retain John S. Martin Jr., a former US District Judge for the Southern District of New York, and colleagues at <span class="new">Debevoise &amp; Plimpton LLP</span>, to investigate Vioxx study results and communications conducted by Merck. The report, which Merck called the "Martin Report", was published in February 2006. The report found that Merck's senior management acted in good faith, and that the confusion over the clinical safety of Vioxx was due to the sales team's overzealous behavior. The report that was filed gave a timeline of the events surrounding Vioxx and stated that Merck intended to operate honestly throughout the process. Any mistakes that were made regarding the mishandling of clinical trial results and withholding of information were described as the result of oversight, not malicious behavior. The report did conclude that the Merck's marketing team exaggerated the safety of Vioxx and replaced truthful information with sales tactics. Merck was satisfied with the findings of the report it had commissioned, and promised to consider the recommendations.<span class="mw-ref" id="cite_ref-Martin_report_2006_64-0"><a href="#cite_note-Martin_report_2006-64" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span> The report was criticised in the press as self-serving. Merck insisted that the report was independent and Merck "had no effect at all on the findings and the conclusions". Merck hoped that the report would improve public perception of Merck.<span class="mw-ref" id="cite_ref-nothing_wrong_63-1"><a href="#cite_note-nothing_wrong-63" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="FDA_position">FDA position</h2></summary>
    
<p>In 2005, advisory panels in both the US and Canada encouraged the return of rofecoxib to the market, stating that Rofecoxib's benefits outweighed the risks for some patients. The FDA advisory panel voted 17-15 to allow the drug to return to the market despite being found to increase heart risk. The vote in Canada was 12-1, and the Canadian panel noted that the cardiovascular risks from rofecoxib seemed to be no worse than those from <a href="Ibuprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibuprofen" title="Ibuprofen">ibuprofen</a>—though the panel stated that further study was needed for all NSAIDs to fully understand their risk profiles. Notwithstanding these recommendations, Merck has not returned rofecoxib to the market.<span class="mw-ref" id="cite_ref-65"><a href="#cite_note-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span><span class="mw-ref" id="cite_ref-66"><a href="#cite_note-66" style="counter-reset: mw-Ref 66;"><span class="mw-reflink-text">[66]</span></a></span></p>

<p>Following the 2005 FDA Advisory Committee, the FDA issued a memo concluding that data from large long-term controlled clinical trials do not clearly demonstrate that COX-2 selective agents (including rofecoxib) have a greater risk of serious cardiovascular events than non-selective NSAIDs.<span class="mw-ref" id="cite_ref-67"><a href="#cite_note-67" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span></p>

<p>In 2015, the FDA reinforced this conclusion, stating that the available data support a dose and duration dependent class effect of an increased risk of serious adverse cardiovascular events for COX-2 selective and non-selective NSAIDs.<span class="mw-ref" id="cite_ref-fda.gov_6-1"><a href="#cite_note-fda.gov-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Litigation">Litigation</h2></summary>
    
<p>By March 2006, there were over 10,000 cases and 190 class actions filed against Merck<span class="mw-ref" id="cite_ref-Petryna_Experiments_Travel_2009_68-0"><a href="#cite_note-Petryna_Experiments_Travel_2009-68" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span> over adverse cardiovascular events associated with rofecoxib and the adequacy of Merck's warnings. The first wrongful death trial, <i>Rogers v. Merck</i>, was scheduled in Alabama in the spring of 2005, but was postponed after Merck argued that the plaintiff had falsified evidence of rofecoxib use.<span class="mw-ref" id="cite_ref-69"><a href="#cite_note-69" style="counter-reset: mw-Ref 69;"><span class="mw-reflink-text">[69]</span></a></span></p>

<p>On August 19, 2005, a jury in Texas voted 10-2 to hold Merck liable for the death of Robert Ernst, a 59-year-old man who allegedly died of a rofecoxib-induced heart attack. Merck argued that the death was due to cardiac arrhythmia, which had not been shown to be associated with rofecoxib use. The jury awarded Carol Ernst, widow of Robert Ernst, $253.4 million in damages. This award was capped at no more than US$26.1 million because of punitive damages limits under Texas law.<span class="mw-ref" id="cite_ref-70"><a href="#cite_note-70" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></span> Merck appealed and the verdict was overturned in 2008.<span class="mw-ref" id="cite_ref-71"><a href="#cite_note-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span>
On November 3, 2005, Merck won the second case <i>Humeston v. Merck</i>, a personal injury case, in Atlantic City, New Jersey. The plaintiff experienced a mild myocardial infarction and claimed that rofecoxib was responsible, after having taken it for two months. Merck argued that there was no evidence that rofecoxib was the cause of Humeston's injury and that there is no scientific evidence linking rofecoxib to cardiac events with short durations of use. The jury ruled that Merck had adequately warned doctors and patients of the drug's risk.<span class="mw-ref" id="cite_ref-72"><a href="#cite_note-72" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span></p>

<p>The first federal trial on rofecoxib, <i>Plunkett v. Merck</i>, began on November 29, 2005 in Houston. The trial ended on December 12, 2005 when Judge Eldon E. Fallon of U.S. District Court declared a mistrial because of a hung jury with an eight to one majority, favoring the defense. Upon retrial in February 2006 in New Orleans, where the Vioxx multidistrict litigation (MDL) is based, a jury found Merck not liable, even though the plaintiffs had the <i>NEJM</i> editor testify as to his objections to the VIGOR study.<span class="mw-ref" id="cite_ref-NYT_Berenson_2005_73-0"><a href="#cite_note-NYT_Berenson_2005-73" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></span></p>

<p>On January 30, 2006, a New Jersey state court dismissed a case brought by Edgar Lee Boyd, who blamed Vioxx for gastrointestinal bleeding that he experienced after taking the drug. The judge said that Boyd failed to prove the drug caused his stomach pain and internal bleeding.</p>

<p>In January 2006, <i>Garza v. Merck</i> began trial in Rio Grande City, Texas. The plaintiff, a 71-year-old smoker with heart disease, had a fatal heart attack three weeks after finishing a one-week sample of rofecoxib. On April 21, 2006 the jury awarded the plaintiff $7 million compensatory and $25 million punitive. The <span class="new">Texas state court of appeals</span> in San Antonio later ruled Garza's fatal heart attack probably resulted from pre-existing health conditions unrelated to his taking of Vioxx, thus reversing the $32 million jury award.<span class="mw-ref" id="cite_ref-74"><a href="#cite_note-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span></p>

<p>On April 5, 2006, a jury held Merck liable for the heart attack of 77-year-old John McDarby, and awarded McDarby $4.5 million in compensatory damages based on Merck's failure to properly warn of Vioxx safety risks. After a hearing on April 11, 2006, the jury also awarded Mr McDarby an additional $9 million in punitive damages. The same jury found Merck not liable for the heart attack of 60-year-old Thomas Cona, a second plaintiff in the trial, but was liable for fraud in the sale of the drug to Cona.</p>

<p>In March 2010, an Australian class-action lawsuit against Merck ruled that Vioxx doubled the risk of heart attacks, and that Merck had breached the Trade Practices Act by selling a drug which was unfit for sale.<span class="mw-ref" id="cite_ref-75"><a href="#cite_note-75" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span></p>

<p>By November 2007 Merck announced that it agreed on a mass tort settlement of $4.85 billion between Merck and the lawyers of 27,000 individual lawsuits with a try-every-case strategy as opposed to a class action lawsuit if "85 percent of the plaintiffs sign up".<span class="mw-ref" id="cite_ref-NYT_Merck_2007_76-0"><a href="#cite_note-NYT_Merck_2007-76" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></span><span class="mw-ref" id="cite_ref-NYT_2008_Liptak_77-0"><a href="#cite_note-NYT_2008_Liptak-77" style="counter-reset: mw-Ref 77;"><span class="mw-reflink-text">[77]</span></a></span> After the settlement, the lawyers for the case disputed the $315 million awarded in legal fees.<span class="mw-ref" id="cite_ref-thenalfa.org_78-0"><a href="#cite_note-thenalfa.org-78" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></span><span class="mw-ref" id="cite_ref-79"><a href="#cite_note-79" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span> Ultimately, the judge determined how the fees would be awarded to the plaintiff's attorneys.<span class="mw-ref" id="cite_ref-80"><a href="#cite_note-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span> Judge Eldon E. Fallon of the United States District Court for the Eastern District of Louisiana additionally ordered the plaintiff lawyers to cap their fees at 32% of the settlement amount.<span class="mw-ref" id="cite_ref-81"><a href="#cite_note-81" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></span></p>

<p>The above dispute over lawyer fees has caused scholars and observers to consider tort reform throughout the country. Articles on the subject include <i>The Vioxx Litigation: A Critical Look at Trial Tactics, the Tort System, and the Roles of Lawyers in Mass Tort Litigation</i><span class="mw-ref" id="cite_ref-McClellan_2008_82-0"><a href="#cite_note-McClellan_2008-82" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></span> and <i>10 Years of Tort Reform in Texas Bring Fewer Suits, Lower Payouts.</i><span class="mw-ref" id="cite_ref-83"><a href="#cite_note-83" style="counter-reset: mw-Ref 83;"><span class="mw-reflink-text">[83]</span></a></span></p>

<p>In November 2011, Merck announced a civil settlement with the <span class="new">US Attorney's Office for the District of Massachusetts</span>, and individually with 43 US states and the District of Columbia, to resolve civil claims relating to Vioxx.<span class="mw-ref" id="cite_ref-84"><a href="#cite_note-84" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></span>  Under the terms of the settlement, Merck agreed to pay two-thirds of a previously recorded $950 million reserve charge in exchange for release from civil liability.  Litigation with seven additional states remains outstanding.  Under separate criminal proceedings, Merck pleaded guilty to a federal misdemeanor charge relating to the marketing of the drug across state lines, incurring a fine of $321.6 million.<span class="mw-ref" id="cite_ref-85"><a href="#cite_note-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Possible_return_to_market">Possible return to market</h2></summary>
    
<p>In November 2017, Massachusetts-based <span class="new">Tremeau Pharmaceuticals</span> announced its plan to return rofecoxib (TRM-201) to market as a treatment for hemophilic arthropathy (HA).  Tremeau announced that the FDA had granted an orphan designation for TRM-201 (rofecoxib) for the treatment of HA, and that they had received FDA feedback on their development plan.<span class="mw-ref" id="cite_ref-Tremeau_Pharmaceuticals_News_7-1"><a href="#cite_note-Tremeau_Pharmaceuticals_News-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span>  HA is a degenerative joint disease caused by recurrent intra-articular bleeding.  It is the largest cause of morbidity in patients with hemophilia and has no currently approved treatment options in the United States.  Traditional NSAIDs are avoided in this population due to their effects on platelet aggregation and risk of gastrointestinal ulcers,<span class="mw-ref" id="cite_ref-Srivastava_e1–e47_8-1"><a href="#cite_note-Srivastava_e1–e47-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> and high potency opioids are the current standard of care in treating HA.<span class="mw-ref" id="cite_ref-Forsyth_1549_9-1"><a href="#cite_note-Forsyth_1549-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>

<p>In March 2019 Tremeau announced that they had hired as chief development officer a former Merck employee who had been a product development team leader and also was responsible for executive oversight for numerous clinical trials for the COX-2 inhibitor VIOXX (rofecoxib).  Tremeau also announced an upcoming clinical trial for rofecoxib and were seeking investigators.<span class="mw-ref" id="cite_ref-86"><a href="#cite_note-86" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span><span class="mw-ref" id="cite_ref-87"><a href="#cite_note-87" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="See_also">See also</h2></summary>
    
<ul><li>COX-2 selective inhibitor</li>
<li>Discovery and development of cyclooxygenase 2 inhibitors</li>
<li>David Graham (epidemiologist)</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Footnotes">Footnotes</h2></summary>
    
<div class="reflist columns references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="mw-references references"><li id="cite_note-1"> <span id="mw-reference-text-cite_note-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21647_vioxx_lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21647_vioxx_lbl.pdf'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21647_vioxx_lbl.pdf" class="external text external">"Vioxx PI"</a> <span class="cs1-format">(PDF)</span>. FDA.</cite></span></li><li id="cite_note-NPR_Merck_2004-2"> <span id="mw-reference-text-cite_note-NPR_Merck_2004-2" class="mw-reference-text"><cite id="CITEREFKnox2004" class="citation cs2">Knox R (September 30, 2004), <a href="javascript:if(confirm('https://web.archive.org/web/20101111103315/http://www.npr.org/templates/story/story.php?storyId=4054991  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20101111103315/http://www.npr.org/templates/story/story.php?storyId=4054991'" tppabs="https://web.archive.org/web/20101111103315/http://www.npr.org/templates/story/story.php?storyId=4054991" class="external text external"><i>Merck Pulls Arthritis Drug Vioxx from Market</i></a>, archived from <a href="javascript:if(confirm('https://www.npr.org/templates/story/story.php?storyId=4054991  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.npr.org/templates/story/story.php?storyId=4054991'" tppabs="https://www.npr.org/templates/story/story.php?storyId=4054991" class="external text external">the original</a> on November 11, 2010<span class="reference-accessdate">, retrieved <span class="nowrap">December 24,</span> 2016</span></cite></span></li><li id="cite_note-3"> <span id="mw-reference-text-cite_note-3" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.newscientist.com/article/dn6918-up-to-140000-heart-attacks-linked-to-vioxx.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.newscientist.com/article/dn6918-up-to-140000-heart-attacks-linked-to-vioxx.html'" tppabs="https://www.newscientist.com/article/dn6918-up-to-140000-heart-attacks-linked-to-vioxx.html" class="external text external">"Up to 140,000 heart attacks linked to Vioxx"</a>. <i>New Scientist</i>. 2005-01-25. p.<span>&nbsp;</span>1.</cite></span></li><li id="cite_note-4"> <span id="mw-reference-text-cite_note-4" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.nytimes.com/2006/12/07/business/07drug.html?ex=1323147600&en=19d27b5814f1c1e8&ei=5088&partner=rssnyt&emc=rss  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2006/12/07/business/07drug.html?ex=1323147600&en=19d27b5814f1c1e8&ei=5088&partner=rssnyt&emc=rss'" tppabs="https://www.nytimes.com/2006/12/07/business/07drug.html?ex=1323147600&en=19d27b5814f1c1e8&ei=5088&partner=rssnyt&emc=rss" class="external text external">"Merck Sees Slightly Higher 2007 Earnings"</a>. <i>New York Times</i>. Reuters. 2006-12-07. p.<span>&nbsp;</span>A1.</cite></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM106201.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM106201.pdf'" tppabs="https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM106201.pdf" class="external text external">"Analysis and recommendations for Agency action regarding nonsteroidal anti-inflammatory drugs and cardiovascular risk"</a> <span class="cs1-format">(PDF)</span>. <i>FDA</i>.</cite></span></li><li id="cite_note-fda.gov-6"> <span id="mw-reference-text-cite_note-fda.gov-6" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/Drugs/DrugSafety/ucm451800.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Drugs/DrugSafety/ucm451800.htm'" tppabs="https://www.fda.gov/Drugs/DrugSafety/ucm451800.htm" class="external text external">"FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes"</a>. <i>FDA</i>. 18 June 2019.</cite></span></li><li id="cite_note-Tremeau_Pharmaceuticals_News-7"> <span id="mw-reference-text-cite_note-Tremeau_Pharmaceuticals_News-7" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.tremeaurx.com/news  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.tremeaurx.com/news'" tppabs="https://www.tremeaurx.com/news" class="external text external">"Tremeau Pharmaceuticals News"</a>. <i>Tremeau Pharmaceuticals</i>.</cite></span></li><li id="cite_note-Srivastava_e1–e47-8"> <span id="mw-reference-text-cite_note-Srivastava_e1–e47-8" class="mw-reference-text"><cite id="CITEREFSrivastavaBrewerMauser-BunschotenKey2013" class="citation journal cs1">Srivastava, A.; Brewer, A. K.; Mauser-Bunschoten, E. P.; Key, N. S.; Kitchen, S.; Llinas, A.; Ludlam, C. A.; Mahlangu, J. N.; Mulder, K. (January 2013). <a href="javascript:if(confirm('https://semanticscholar.org/paper/fce5347ca70866cc588194738bbcf25e887933cf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://semanticscholar.org/paper/fce5347ca70866cc588194738bbcf25e887933cf'" tppabs="https://semanticscholar.org/paper/fce5347ca70866cc588194738bbcf25e887933cf" class="external text external">"Guidelines for the management of hemophilia"</a>. <i>Haemophilia</i>. <b>19</b> (1): e1–e47. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-2516.2012.02909.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-2516.2012.02909.x'" tppabs="https://doi.org/10.1111%2Fj.1365-2516.2012.02909.x" class="external text external">10.1111/j.1365-2516.2012.02909.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22776238  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22776238'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22776238" class="external text external">22776238</a>.</cite></span></li><li id="cite_note-Forsyth_1549-9"> <span id="mw-reference-text-cite_note-Forsyth_1549-9" class="mw-reference-text"><cite id="CITEREFForsythWitkopLambingGarrido2015" class="citation journal cs1">Forsyth, Angela; Witkop, Michelle; Lambing, Angela; Garrido, Cesar; Dunn, Spencer; Cooper, David L.; Nugent, Diane (October 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631419  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631419'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631419" class="external text external">"Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study"</a>. <i>Patient Preference and Adherence</i>. <b>9</b>: 1549–1560. doi:<a href="javascript:if(confirm('https://doi.org/10.2147%2FPPA.S87659  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2147%2FPPA.S87659'" tppabs="https://doi.org/10.2147%2FPPA.S87659" class="external text external">10.2147/PPA.S87659</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1177-889X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1177-889X'" tppabs="https://www.worldcat.org/issn/1177-889X" class="external text external">1177-889X</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631419  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631419'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631419" class="external text external">4631419</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26604708  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26604708'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26604708" class="external text external">26604708</a>.</cite></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite id="CITEREFUshiyamaYamadaMurakamiKumakura2008" class="citation journal cs1">Ushiyama, Shigeru; Yamada, Tomoko; Murakami, Yukiko; Kumakura, Sei-ichiro; Inoue, Shin-ichi; Suzuki, Keisuke; Nakao, Akira; Kawara, Akihiro; Kimura, Tomio (2008-01-06). "Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects". <i>European Journal of Pharmacology</i>. <b>578</b> (1): 76–86. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ejphar.2007.08.034  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ejphar.2007.08.034'" tppabs="https://doi.org/10.1016%2Fj.ejphar.2007.08.034" class="external text external">10.1016/j.ejphar.2007.08.034</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0014-2999  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0014-2999'" tppabs="https://www.worldcat.org/issn/0014-2999" class="external text external">0014-2999</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17920584  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17920584'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17920584" class="external text external">17920584</a>.</cite></span></li><li id="cite_note-Bombardier_2000-11"> <span id="mw-reference-text-cite_note-Bombardier_2000-11" class="mw-reference-text"><cite id="CITEREFBombardierLaineReicinShapiro2000" class="citation journal cs1">Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ (November 2000). "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group". <i>The New England Journal of Medicine</i>. <b>343</b> (21): 1520–8, 2 p following 1528. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJM200011233432103  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJM200011233432103'" tppabs="https://doi.org/10.1056%2FNEJM200011233432103" class="external text external">10.1056/NEJM200011233432103</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11087881  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11087881'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11087881" class="external text external">11087881</a>.</cite></span></li><li id="cite_note-Merck-12"> <span id="mw-reference-text-cite_note-Merck-12" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.merck.com/product/usa/pi_circulars/v/vioxx/vioxx_pi.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.merck.com/product/usa/pi_circulars/v/vioxx/vioxx_pi.pdf'" tppabs="http://www.merck.com/product/usa/pi_circulars/v/vioxx/vioxx_pi.pdf" class="external text external">"VIOXX® (rofecoxib tablets and oral suspension)<span>&nbsp;</span>: DESCRIPTION"</a> <span class="cs1-format">(PDF)</span>. Merck.com<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-Gold-13"> <span id="mw-reference-text-cite_note-Gold-13" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.mdconsult.com/das/pharm/body/181267313-3/946823742/full/2399  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.mdconsult.com/das/pharm/body/181267313-3/946823742/full/2399'" tppabs="http://www.mdconsult.com/das/pharm/body/181267313-3/946823742/full/2399" class="external text external">"MD Consult - Important Notice"</a>. Mdconsult.com<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-Davies-14"> <span id="mw-reference-text-cite_note-Davies-14" class="mw-reference-text"><cite id="CITEREFDaviesTengSkjodt2003" class="citation journal cs1">Davies NM, Teng XW, Skjodt NM (2003). "Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor". <i>Clinical Pharmacokinetics</i>. <b>42</b> (6): 545–56. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003088-200342060-00004  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003088-200342060-00004'" tppabs="https://doi.org/10.2165%2F00003088-200342060-00004" class="external text external">10.2165/00003088-200342060-00004</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12793839  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12793839'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12793839" class="external text external">12793839</a>.</cite></span></li><li id="cite_note-Padi-15"> <span id="mw-reference-text-cite_note-Padi-15" class="mw-reference-text"><cite id="CITEREFPadiKulkarni2004" class="citation journal cs1">Padi SS, Kulkarni SK (October 2004). "Differential effects of naproxen and rofecoxib on the development of hypersensitivity following nerve injury in rats". <i>Pharmacology Biochemistry and Behavior</i>. <b>79</b> (2): 349–58. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.pbb.2004.08.005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.pbb.2004.08.005'" tppabs="https://doi.org/10.1016%2Fj.pbb.2004.08.005" class="external text external">10.1016/j.pbb.2004.08.005</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15501312  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15501312'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15501312" class="external text external">15501312</a>.</cite></span></li><li id="cite_note-Scott-16"> <span id="mw-reference-text-cite_note-Scott-16" class="mw-reference-text"><cite id="CITEREFScottLamb1999" class="citation journal cs1">Scott LJ, Lamb HM (September 1999). "Rofecoxib". <i>Drugs</i>. <b>58</b> (3): 499–505, discussion 506–7. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003495-199958030-00016  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003495-199958030-00016'" tppabs="https://doi.org/10.2165%2F00003495-199958030-00016" class="external text external">10.2165/00003495-199958030-00016</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10493277  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10493277'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10493277" class="external text external">10493277</a>.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21647_vioxx_lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21647_vioxx_lbl.pdf'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21647_vioxx_lbl.pdf" class="external text external">"Vioxx PI"</a> <span class="cs1-format">(PDF)</span>. <i>FDA</i>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite id="CITEREFTehraniDharmalingam2004" class="citation journal cs1">Tehrani R, Dharmalingam M (November 2004). <a href="javascript:if(confirm('http://www.ijdvl.com/article.asp?issn=0378-6323;year=2004;volume=70;issue=6;spage=345;epage=348;aulast=Tehrani  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ijdvl.com/article.asp?issn=0378-6323;year=2004;volume=70;issue=6;spage=345;epage=348;aulast=Tehrani'" tppabs="http://www.ijdvl.com/article.asp?issn=0378-6323;year=2004;volume=70;issue=6;spage=345;epage=348;aulast=Tehrani" class="external text external">"Management of premenstrual acne with Cox-2 inhibitors: a placebo controlled study"</a>. <i>Indian Journal of Dermatology, Venereology and Leprology</i>. <b>70</b> (6): 345–8. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17642660  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17642660'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17642660" class="external text external">17642660</a>.</cite></span></li><li id="cite_note-WSJ-3-2009-19"> <span id="mw-reference-text-cite_note-WSJ-3-2009-19" class="mw-reference-text"><cite id="CITEREFWinstein2009" class="citation news cs1">Winstein KJ (March 11, 2009). <a href="javascript:if(confirm('https://www.wsj.com/articles/SB123672510903888207?mod=loomia&loomia_si=t0:a16:g2:r1:c0.0270612:b22894832  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.wsj.com/articles/SB123672510903888207?mod=loomia&loomia_si=t0:a16:g2:r1:c0.0270612:b22894832'" tppabs="https://www.wsj.com/articles/SB123672510903888207?mod=loomia&loomia_si=t0:a16:g2:r1:c0.0270612:b22894832" class="external text external">"Top Pain Scientist Fabricated Data in Studies, Hospital Says"</a>. <i>The Wall Street Journal</i>.</cite></span></li><li id="cite_note-WSJ_Mathews_2004-20"> <span id="mw-reference-text-cite_note-WSJ_Mathews_2004-20" class="mw-reference-text"><cite id="CITEREFMathewsMartinez2004" class="citation cs2">Mathews AW, Martinez B (November 1, 2004), <a href="javascript:if(confirm('https://www.wsj.com/articles/SB109926864290160719  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.wsj.com/articles/SB109926864290160719'" tppabs="https://www.wsj.com/articles/SB109926864290160719" class="external text external"><i>E-Mails Suggest Merck Knew Vioxx's Dangers at Early Stage As Heart-Risk Evidence Rose: Officials Played Hardball; Internal Message: 'Dodge!'</i></a>, Wall Street Journal</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21647_vioxx_lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21647_vioxx_lbl.pdf'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21647_vioxx_lbl.pdf" class="external text external">"Vioxx PI"</a> <span class="cs1-format">(PDF)</span>. <i>FDA</i>.</cite></span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21647_vioxx_lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21647_vioxx_lbl.pdf'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21647_vioxx_lbl.pdf" class="external text external">"Vioxx PI"</a> <span class="cs1-format">(PDF)</span>. <i>FDA</i>.</cite></span></li><li id="cite_note-Cardio-23"> <span id="mw-reference-text-cite_note-Cardio-23" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20150324043011/http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150324043011/http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf'" tppabs="https://web.archive.org/web/20150324043011/http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf" class="external text external">"NAME OF DRUG: Rofecoxib (MK-0966)<span>&nbsp;</span>: Memorandum"</a> <span class="cs1-format">(PDF)</span>. Fda.gov. Archived from <a href="javascript:if(confirm('http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf'" tppabs="http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 24 March 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite id="CITEREFMartin2006" class="citation web cs1">Martin, John S. (September 5, 2006). <a href="javascript:if(confirm('https://web.archive.org/web/20101220235745/http://www.merck.com/newsroom/vioxx/pdf/020-appendix_h_criticism_of_vioxxs_renal_safety_profile.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20101220235745/http://www.merck.com/newsroom/vioxx/pdf/020-appendix_h_criticism_of_vioxxs_renal_safety_profile.pdf'" tppabs="https://web.archive.org/web/20101220235745/http://www.merck.com/newsroom/vioxx/pdf/020-appendix_h_criticism_of_vioxxs_renal_safety_profile.pdf" class="external text external">"Report of John S. Martin, Jr. to the Special Committee of the Board of Directors of Merck &amp; Co., Inc. Concerning the Conduct of Senior Management in the Development and Marketing of Vioxx: Appendix H"</a> <span class="cs1-format">(PDF)</span>. Debevoise &amp; Plimpton LLP. p.<span>&nbsp;</span>2. Archived from <a href="javascript:if(confirm('http://www.merck.com/newsroom/vioxx/pdf/020-appendix_h_criticism_of_vioxxs_renal_safety_profile.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.merck.com/newsroom/vioxx/pdf/020-appendix_h_criticism_of_vioxxs_renal_safety_profile.pdf'" tppabs="http://www.merck.com/newsroom/vioxx/pdf/020-appendix_h_criticism_of_vioxxs_renal_safety_profile.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on December 20, 2010.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><a href="javascript:if(confirm('http://www.powerlinefacts.com/Sciam_article_on_lobbying.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.powerlinefacts.com/Sciam_article_on_lobbying.htm'" tppabs="http://www.powerlinefacts.com/Sciam_article_on_lobbying.htm" class="external autonumber external"></a> <a href="javascript:if(confirm('https://web.archive.org/web/20150104200843/http://www.powerlinefacts.com/Sciam_article_on_lobbying.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150104200843/http://www.powerlinefacts.com/Sciam_article_on_lobbying.htm'" tppabs="https://web.archive.org/web/20150104200843/http://www.powerlinefacts.com/Sciam_article_on_lobbying.htm" class="external text external">Archived</a><span> January 4, 2015, at the </span>Wayback Machine</span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><a href="javascript:if(confirm('http://www.saferdrugsnow.org/documents/vio/E-mailreCarloPatronoVIGOR.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.saferdrugsnow.org/documents/vio/E-mailreCarloPatronoVIGOR.pdf'" tppabs="http://www.saferdrugsnow.org/documents/vio/E-mailreCarloPatronoVIGOR.pdf" class="external autonumber external"></a>  <a href="javascript:if(confirm('https://web.archive.org/web/20060625011642/http://www.saferdrugsnow.org/documents/vio/E-mailreCarloPatronoVIGOR.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20060625011642/http://www.saferdrugsnow.org/documents/vio/E-mailreCarloPatronoVIGOR.pdf'" tppabs="https://web.archive.org/web/20060625011642/http://www.saferdrugsnow.org/documents/vio/E-mailreCarloPatronoVIGOR.pdf" class="external text external">Archived</a><span> June 25, 2006, at the </span>Wayback Machine</span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite id="CITEREFKarhaTopol2004" class="citation journal cs1">Karha, J.; Topol, E. J. (2004). <a href="javascript:if(confirm('https://semanticscholar.org/paper/804d74b9ae23c4538e1228e43e7df06a1cfc4647  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://semanticscholar.org/paper/804d74b9ae23c4538e1228e43e7df06a1cfc4647'" tppabs="https://semanticscholar.org/paper/804d74b9ae23c4538e1228e43e7df06a1cfc4647" class="external text external">"The sad story of Vioxx, and what we should learn from it"</a>. <i>Cleveland Clinic Journal of Medicine</i>. <b>71</b> (12): 933–934. doi:<a href="javascript:if(confirm('https://doi.org/10.3949%2Fccjm.71.12.933  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3949%2Fccjm.71.12.933'" tppabs="https://doi.org/10.3949%2Fccjm.71.12.933" class="external text external">10.3949/ccjm.71.12.933</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15641522  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15641522'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15641522" class="external text external">15641522</a>.</cite></span></li><li id="cite_note-28"> <span id="mw-reference-text-cite_note-28" class="mw-reference-text"><cite id="CITEREFSolomonGlynnLevinAvorn2002" class="citation journal cs1">Solomon DH, Glynn RJ, Levin R, Avorn J (May 2002). <a href="javascript:if(confirm('https://doi.org/10.1001/archinte.162.10.1099  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001/archinte.162.10.1099'" tppabs="https://doi.org/10.1001/archinte.162.10.1099" class="external text external">"Nonsteroidal anti-inflammatory drug use and acute myocardial infarction"</a>. <i>Archives of Internal Medicine</i>. <b>162</b> (10): 1099–104. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1001%2Farchinte.162.10.1099  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Farchinte.162.10.1099'" tppabs="https://doi.org/10.1001%2Farchinte.162.10.1099" class="external text external">10.1001/archinte.162.10.1099</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12020178  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12020178'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12020178" class="external text external">12020178</a>.</cite></span></li><li id="cite_note-29"> <span id="mw-reference-text-cite_note-29" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM166383.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM166383.pdf'" tppabs="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM166383.pdf" class="external text external">"Warning Letter"</a> <span class="cs1-format">(PDF)</span>. Fda.gov<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-Curfman_2006a-30"> <span id="mw-reference-text-cite_note-Curfman_2006a-30" class="mw-reference-text"><cite id="CITEREFCurfmanMorrisseyDrazen2005" class="citation journal cs1">Curfman GD, Morrissey S, Drazen JM (December 2005). <a href="javascript:if(confirm('https://semanticscholar.org/paper/c55f4d19812b1e8e805e21b42d140932f60ff089  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://semanticscholar.org/paper/c55f4d19812b1e8e805e21b42d140932f60ff089'" tppabs="https://semanticscholar.org/paper/c55f4d19812b1e8e805e21b42d140932f60ff089" class="external text external">"Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8"</a>. <i>The New England Journal of Medicine</i>. <b>353</b> (26): 2813–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMe058314  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMe058314'" tppabs="https://doi.org/10.1056%2FNEJMe058314" class="external text external">10.1056/NEJMe058314</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16339408  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16339408'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16339408" class="external text external">16339408</a>.</cite></span></li><li id="cite_note-31"> <span id="mw-reference-text-cite_note-31" class="mw-reference-text"><a href="javascript:if(confirm('https://www.forbes.com/work/feeds/ap/2006/02/13/ap2523250.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.forbes.com/work/feeds/ap/2006/02/13/ap2523250.html'" tppabs="https://www.forbes.com/work/feeds/ap/2006/02/13/ap2523250.html" class="external autonumber external"></a> </span></li><li id="cite_note-Curfman_2006b-32"> <span id="mw-reference-text-cite_note-Curfman_2006b-32" class="mw-reference-text"><cite id="CITEREFCurfmanMorrisseyDrazen2006" class="citation journal cs1">Curfman GD, Morrissey S, Drazen JM (March 2006). "Expression of concern reaffirmed". <i>The New England Journal of Medicine</i>. <b>354</b> (11): 1193. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMe068054  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMe068054'" tppabs="https://doi.org/10.1056%2FNEJMe068054" class="external text external">10.1056/NEJMe068054</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16495386  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16495386'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16495386" class="external text external">16495386</a>.</cite></span></li><li id="cite_note-33"> <span id="mw-reference-text-cite_note-33" class="mw-reference-text"><cite id="CITEREFBombardierLaineBurgos-VargasDavis2006" class="citation journal cs1">Bombardier C, Laine L, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, Weaver A (March 2006). "Response to expression of concern regarding VIGOR study". <i>The New England Journal of Medicine</i>. <b>354</b> (11): 1196–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMc066096  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMc066096'" tppabs="https://doi.org/10.1056%2FNEJMc066096" class="external text external">10.1056/NEJMc066096</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16495387  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16495387'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16495387" class="external text external">16495387</a>.</cite></span></li><li id="cite_note-34"> <span id="mw-reference-text-cite_note-34" class="mw-reference-text"><cite id="CITEREFLowe2006" class="citation web cs1">Lowe, Derek (2006-02-22). <a href="javascript:if(confirm('http://blogs.sciencemag.org/pipeline/archives/2006/02/22/nejm_vs_its_contributors_round_two/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://blogs.sciencemag.org/pipeline/archives/2006/02/22/nejm_vs_its_contributors_round_two/'" tppabs="http://blogs.sciencemag.org/pipeline/archives/2006/02/22/nejm_vs_its_contributors_round_two/" class="external text external">"NEJM vs. Its Contributors, Round Two"</a>. Science<span class="reference-accessdate">. Retrieved <span class="nowrap">20 November</span> 2015</span>.</cite></span></li><li id="cite_note-35"> <span id="mw-reference-text-cite_note-35" class="mw-reference-text"><a href="javascript:if(confirm('http://dimer.tamu.edu/simplog/archive.php?blogid=3&pid=3293  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://dimer.tamu.edu/simplog/archive.php?blogid=3&pid=3293'" tppabs="http://dimer.tamu.edu/simplog/archive.php?blogid=3&pid=3293" class="external autonumber external"></a>  <a href="javascript:if(confirm('https://web.archive.org/web/20120610235819/http://dimer.tamu.edu/simplog/archive.php?blogid=3&pid=3293  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120610235819/http://dimer.tamu.edu/simplog/archive.php?blogid=3&pid=3293'" tppabs="https://web.archive.org/web/20120610235819/http://dimer.tamu.edu/simplog/archive.php?blogid=3&pid=3293" class="external text external">Archived</a><span> June 10, 2012, at the </span>Wayback Machine</span></li><li id="cite_note-36"> <span id="mw-reference-text-cite_note-36" class="mw-reference-text"><a href="javascript:if(confirm('http://genetics.case.edu/faculty2.php?fac=ejt9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://genetics.case.edu/faculty2.php?fac=ejt9'" tppabs="http://genetics.case.edu/faculty2.php?fac=ejt9" class="external autonumber external"></a>  <a href="javascript:if(confirm('https://web.archive.org/web/20060908042122/http://genetics.case.edu/faculty2.php?fac=ejt9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20060908042122/http://genetics.case.edu/faculty2.php?fac=ejt9'" tppabs="https://web.archive.org/web/20060908042122/http://genetics.case.edu/faculty2.php?fac=ejt9" class="external text external">Archived</a><span> September 8, 2006, at the </span>Wayback Machine</span></li><li id="cite_note-37"> <span id="mw-reference-text-cite_note-37" class="mw-reference-text"><a href="javascript:if(confirm('http://www.medicinenet.com/script/main/art.asp?articlekey=56384&page=2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medicinenet.com/script/main/art.asp?articlekey=56384&page=2'" tppabs="http://www.medicinenet.com/script/main/art.asp?articlekey=56384&page=2" class="external autonumber external"></a> </span></li><li id="cite_note-38"> <span id="mw-reference-text-cite_note-38" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.beasleyallen.com/news/vioxx-plaintiffs-seek-mistrial-after-allegation-on-merck-study/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.beasleyallen.com/news/vioxx-plaintiffs-seek-mistrial-after-allegation-on-merck-study/'" tppabs="http://www.beasleyallen.com/news/vioxx-plaintiffs-seek-mistrial-after-allegation-on-merck-study/" class="external text external">"Vioxx Plaintiffs seek Mistrial after Allegation on Merck Study"</a>. Beasleyallen.com. 2005-12-10<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-WSJ515-39"> <span id="mw-reference-text-cite_note-WSJ515-39" class="mw-reference-text"><cite id="CITEREFDavid_Armstrong2006" class="citation news cs1">David Armstrong (2006-05-15). <a href="javascript:if(confirm('https://www.wsj.com/articles/SB114765430315252591  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.wsj.com/articles/SB114765430315252591'" tppabs="https://www.wsj.com/articles/SB114765430315252591" class="external text external">"How the New England Journal Missed Warning Signs on Vioxx"</a>. <i>Wall Street Journal</i>. p.<span>&nbsp;</span>A1.</cite></span></li><li id="cite_note-40"> <span id="mw-reference-text-cite_note-40" class="mw-reference-text"><cite id="CITEREFBerenson2005" class="citation news cs1">Berenson A (24 April 2005). <a href="javascript:if(confirm('https://www.nytimes.com/2005/04/24/business/evidence-in-vioxx-suits-shows-intervention-by-merck-officials.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2005/04/24/business/evidence-in-vioxx-suits-shows-intervention-by-merck-officials.html'" tppabs="https://www.nytimes.com/2005/04/24/business/evidence-in-vioxx-suits-shows-intervention-by-merck-officials.html" class="external text external">"Evidence in Vioxx Suits Shows Intervention by Merck Officials"</a>. <i>The New York Times</i> <span>–</span> via NYTimes.com.</cite></span></li><li id="cite_note-41"> <span id="mw-reference-text-cite_note-41" class="mw-reference-text"><cite id="CITEREFLattman2006" class="citation web cs1">Lattman P (8 February 2006). <a href="javascript:if(confirm('https://blogs.wsj.com/law/2006/02/08/the-merck-trial-edward-the-scalder-scolnick/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://blogs.wsj.com/law/2006/02/08/the-merck-trial-edward-the-scalder-scolnick/'" tppabs="https://blogs.wsj.com/law/2006/02/08/the-merck-trial-edward-the-scalder-scolnick/" class="external text external">"The Merck Vioxx Litigation: Edward "The Scalder" Scolnick"</a>.</cite></span></li><li id="cite_note-42"> <span id="mw-reference-text-cite_note-42" class="mw-reference-text"><a href="javascript:if(confirm('https://web.duke.edu/kenanethics/CaseStudies/Vioxx.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.duke.edu/kenanethics/CaseStudies/Vioxx.pdf'" tppabs="https://web.duke.edu/kenanethics/CaseStudies/Vioxx.pdf" class="external free external">https://web.duke.edu/kenanethics/CaseStudies/Vioxx.pdf</a></span></li><li id="cite_note-43"> <span id="mw-reference-text-cite_note-43" class="mw-reference-text"><cite id="CITEREFPelayo1999" class="citation web cs1">Pelayo, Juan Carlos (April 30, 1999). <a href="javascript:if(confirm('https://web.archive.org/web/20100310194639/https://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_06_G-FDA-Tab-D-2.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20100310194639/https://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_06_G-FDA-Tab-D-2.pdf'" tppabs="https://web.archive.org/web/20100310194639/https://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_06_G-FDA-Tab-D-2.pdf" class="external text external">"Consultation NDA 21-042. Cardiovascular and Renal Safety database"</a> <span class="cs1-format">(PDF)</span>. Food and Drug Administration: Centre for Drug Evaluation and Research:Division of Cardio-Renal Drug Products, HFD-110. p.<span>&nbsp;</span>4. Archived from <a href="javascript:if(confirm('https://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_06_G-FDA-Tab-D-2.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_06_G-FDA-Tab-D-2.pdf'" tppabs="https://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_06_G-FDA-Tab-D-2.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on March 10, 2010.</cite></span></li><li id="cite_note-44"> <span id="mw-reference-text-cite_note-44" class="mw-reference-text"><cite id="CITEREFEgilmanPresler2011" class="citation journal cs1">Egilman, David S.; Presler, Amos H. (November 1, 2011). <a href="javascript:if(confirm('https://www.bmj.com/rapid-response/2011/11/01/re-selective-learning-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.bmj.com/rapid-response/2011/11/01/re-selective-learning-0'" tppabs="https://www.bmj.com/rapid-response/2011/11/01/re-selective-learning-0" class="external text external">"What have we learnt from Vioxx? Re: On Selective Learning"</a>. <i>BMJ</i>. <b>334</b>: 120.</cite></span></li><li id="cite_note-45"> <span id="mw-reference-text-cite_note-45" class="mw-reference-text"><cite id="CITEREFKonstamWeirReicinShapiro2001" class="citation journal cs1">Konstam, Marvin A.; Weir, Matthew R.; Reicin, Alise; Shapiro, Deborah; Sperling, Rhoda S.; Barr, Eliav; Gertz, Barry J. (2001). <a href="javascript:if(confirm('https://doi.org/10.1161/hc4401.100078  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1161/hc4401.100078'" tppabs="https://doi.org/10.1161/hc4401.100078" class="external text external">"Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib"</a>. <i>Circulation</i>. <b>104</b> (19): 2280–2288. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1161%2Fhc4401.100078  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1161%2Fhc4401.100078'" tppabs="https://doi.org/10.1161%2Fhc4401.100078" class="external text external">10.1161/hc4401.100078</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11696466  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11696466'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11696466" class="external text external">11696466</a>.</cite></span></li><li id="cite_note-Bresalier_2005-46"> <span id="mw-reference-text-cite_note-Bresalier_2005-46" class="mw-reference-text"><cite id="CITEREFBresalierSandlerQuanBolognese2005" class="citation journal cs1">Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (March 2005). <a href="javascript:if(confirm('https://semanticscholar.org/paper/d88471c284c35005dc9c7291e1ef144ab49498aa  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://semanticscholar.org/paper/d88471c284c35005dc9c7291e1ef144ab49498aa'" tppabs="https://semanticscholar.org/paper/d88471c284c35005dc9c7291e1ef144ab49498aa" class="external text external">"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial"</a>. <i>The New England Journal of Medicine</i>. <b>352</b> (11): 1092–102. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa050493  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa050493'" tppabs="https://doi.org/10.1056%2FNEJMoa050493" class="external text external">10.1056/NEJMoa050493</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15713943  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15713943'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15713943" class="external text external">15713943</a>.</cite></span></li><li id="cite_note-Cardio2-47"> <span id="mw-reference-text-cite_note-Cardio2-47" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20011218085732/https://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20011218085732/https://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf'" tppabs="https://web.archive.org/web/20011218085732/https://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf" class="external text external">"NAME OF DRUG: Rofecoxib (MK-0966)<span>&nbsp;</span>: Memorandum"</a> <span class="cs1-format">(PDF)</span>. Fda.gov. Archived from <a href="javascript:if(confirm('https://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf'" tppabs="https://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 18 December 2001<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-48"> <span id="mw-reference-text-cite_note-48" class="mw-reference-text"><cite id="CITEREFKimReicin2004" class="citation journal cs1">Kim PS, Reicin AS (December 2004). "Rofecoxib, Merck, and the FDA". <i>The New England Journal of Medicine</i>. <b>351</b> (27): 2875–8, author reply 2875–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJM200412303512719  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJM200412303512719'" tppabs="https://doi.org/10.1056%2FNEJM200412303512719" class="external text external">10.1056/NEJM200412303512719</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15625342  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15625342'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15625342" class="external text external">15625342</a>.</cite></span></li><li id="cite_note-cox2drugreview.org-49"> <span id="mw-reference-text-cite_note-cox2drugreview.org-49" class="mw-reference-text"><cite id="CITEREFZhangDingSong2006" class="citation journal cs1">Zhang J, Ding EL, Song Y (October 2006). "Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials". <i>JAMA</i>. <b>296</b> (13): 1619–32. doi:<a href="javascript:if(confirm('https://doi.org/10.1001%2Fjama.296.13.jrv60015  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjama.296.13.jrv60015'" tppabs="https://doi.org/10.1001%2Fjama.296.13.jrv60015" class="external text external">10.1001/jama.296.13.jrv60015</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16968832  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16968832'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16968832" class="external text external">16968832</a>.</cite></span></li><li id="cite_note-50"> <span id="mw-reference-text-cite_note-50" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM106201.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM106201.pdf'" tppabs="https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM106201.pdf" class="external text external">"Analysis and recommendations for Agency action regarding nonsteroidal anti-inflammatory drugs and cardiovascular risk"</a> <span class="cs1-format">(PDF)</span>. <i>FDA</i>.</cite></span></li><li id="cite_note-EMEA2005-51"> <span id="mw-reference-text-cite_note-EMEA2005-51" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20080406201636/http://www.emea.europa.eu/pdfs/human/press/pr/20776605en.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20080406201636/http://www.emea.europa.eu/pdfs/human/press/pr/20776605en.pdf'" tppabs="https://web.archive.org/web/20080406201636/http://www.emea.europa.eu/pdfs/human/press/pr/20776605en.pdf" class="external text external">"European Medicines Agency concludes action on COX-2 inhibitors"</a> <span class="cs1-format">(PDF)</span>. European Medicines Agency. Archived from <a href="javascript:if(confirm('http://www.emea.europa.eu/pdfs/human/press/pr/20776605en.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.emea.europa.eu/pdfs/human/press/pr/20776605en.pdf'" tppabs="http://www.emea.europa.eu/pdfs/human/press/pr/20776605en.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 2008-04-06<span class="reference-accessdate">. Retrieved <span class="nowrap">2008-04-16</span></span>.</cite></span></li><li id="cite_note-52"> <span id="mw-reference-text-cite_note-52" class="mw-reference-text"><cite id="CITEREFMcGettiganHenry2011" class="citation journal cs1">McGettigan, Patricia; Henry, David (2011-09-27). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181230  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181230'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181230" class="external text external">"Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies"</a>. <i>PLOS Medicine</i>. <b>8</b> (9): e1001098. doi:<a href="javascript:if(confirm('https://doi.org/10.1371%2Fjournal.pmed.1001098  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1371%2Fjournal.pmed.1001098'" tppabs="https://doi.org/10.1371%2Fjournal.pmed.1001098" class="external text external">10.1371/journal.pmed.1001098</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1549-1676  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1549-1676'" tppabs="https://www.worldcat.org/issn/1549-1676" class="external text external">1549-1676</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181230  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181230'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181230" class="external text external">3181230</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21980265  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21980265'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21980265" class="external text external">21980265</a>.</cite></span></li><li id="cite_note-53"> <span id="mw-reference-text-cite_note-53" class="mw-reference-text"><cite id="CITEREFCoxib_traditional_NSAID_Trialists'_(CNT)_Collaboration2013" class="citation journal cs1">Coxib traditional NSAID Trialists' (CNT) Collaboration (August 2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778977  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778977'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778977" class="external text external">"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials"</a>. <i>The Lancet</i>. <b>382</b> (9894): 769–779. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0140-6736%2813%2960900-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0140-6736%2813%2960900-9'" tppabs="https://doi.org/10.1016%2Fs0140-6736%2813%2960900-9" class="external text external">10.1016/s0140-6736(13)60900-9</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0140-6736  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0140-6736'" tppabs="https://www.worldcat.org/issn/0140-6736" class="external text external">0140-6736</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778977  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778977'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778977" class="external text external">3778977</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23726390  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23726390'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23726390" class="external text external">23726390</a>.</cite></span></li><li id="cite_note-54"> <span id="mw-reference-text-cite_note-54" class="mw-reference-text"><cite id="CITEREFPatronoBaigent2014" class="citation journal cs1">Patrono, Carlo; Baigent, Colin (2014-02-25). <a href="javascript:if(confirm('https://doi.org/10.1161/circulationaha.113.004480  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1161/circulationaha.113.004480'" tppabs="https://doi.org/10.1161/circulationaha.113.004480" class="external text external">"Nonsteroidal Anti-Inflammatory Drugs and the Heart"</a>. <i>Circulation</i>. <b>129</b> (8): 907–916. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1161%2Fcirculationaha.113.004480  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1161%2Fcirculationaha.113.004480'" tppabs="https://doi.org/10.1161%2Fcirculationaha.113.004480" class="external text external">10.1161/circulationaha.113.004480</a></span>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0009-7322  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0009-7322'" tppabs="https://www.worldcat.org/issn/0009-7322" class="external text external">0009-7322</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24566065  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24566065'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24566065" class="external text external">24566065</a>.</cite></span></li><li id="cite_note-55"> <span id="mw-reference-text-cite_note-55" class="mw-reference-text"><cite id="CITEREFNissenYeomansSolomonLüscher2016" class="citation journal cs1">Nissen, Steven E.; Yeomans, Neville D.; Solomon, Daniel H.; Lüscher, Thomas F.; Libby, Peter; Husni, M. Elaine; Graham, David Y.; Borer, Jeffrey S.; Wisniewski, Lisa M. (2016-12-29). <a href="javascript:if(confirm('https://doi.org/10.1056/nejmoa1611593  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056/nejmoa1611593'" tppabs="https://doi.org/10.1056/nejmoa1611593" class="external text external">"Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis"</a>. <i>New England Journal of Medicine</i>. <b>375</b> (26): 2519–2529. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1056%2Fnejmoa1611593  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2Fnejmoa1611593'" tppabs="https://doi.org/10.1056%2Fnejmoa1611593" class="external text external">10.1056/nejmoa1611593</a></span>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0028-4793  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0028-4793'" tppabs="https://www.worldcat.org/issn/0028-4793" class="external text external">0028-4793</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27959716  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27959716'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27959716" class="external text external">27959716</a>.</cite></span></li><li id="cite_note-56"> <span id="mw-reference-text-cite_note-56" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20120417053059/http://www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120417053059/http://www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final.pdf'" tppabs="https://web.archive.org/web/20120417053059/http://www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final.pdf" class="external text external">"Merck Announces Voluntary Worldwide Withdrawal of VIOXX"</a> <span class="cs1-format">(PDF)</span>. Merck.com. Archived from <a href="javascript:if(confirm('http://www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final.pdf'" tppabs="http://www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 17 April 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-NPR_2004-57"> <span id="mw-reference-text-cite_note-NPR_2004-57" class="mw-reference-text"><cite class="citation cs2"><a href="javascript:if(confirm('https://www.npr.org/templates/story/story.php?storyId=4054991  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.npr.org/templates/story/story.php?storyId=4054991'" tppabs="https://www.npr.org/templates/story/story.php?storyId=4054991" class="external text external">"Q&amp;A on the case, following withdrawal announcement"</a>, <i>National Public Radio (NPR)</i>, 2004<span class="reference-accessdate">, retrieved <span class="nowrap">December 24,</span> 2016</span></cite></span></li><li id="cite_note-58"> <span id="mw-reference-text-cite_note-58" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.pbs.org/newshour/show/congress-questions-vioxx-fda  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.pbs.org/newshour/show/congress-questions-vioxx-fda'" tppabs="https://www.pbs.org/newshour/show/congress-questions-vioxx-fda" class="external text external">"Congress Questions Vioxx, FDA"</a>. <i>PBS NewsHour</i>. 2004-11-18<span class="reference-accessdate">. Retrieved <span class="nowrap">2013-06-03</span></span>.</cite></span></li><li id="cite_note-Jüni_2004_Lancet-59"> <span id="mw-reference-text-cite_note-Jüni_2004_Lancet-59" class="mw-reference-text"><cite id="CITEREFJüniNarteyReichenbachSterchi2004" class="citation journal cs1">Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004). "Risk of cardiovascular events and rofecoxib: cumulative meta-analysis". <i>Lancet</i>. <b>364</b> (9450): 2021–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0140-6736%2804%2917514-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0140-6736%2804%2917514-4'" tppabs="https://doi.org/10.1016%2FS0140-6736%2804%2917514-4" class="external text external">10.1016/S0140-6736(04)17514-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15582059  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15582059'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15582059" class="external text external">15582059</a>.</cite></span></li><li id="cite_note-60"> <span id="mw-reference-text-cite_note-60" class="mw-reference-text"><a href="javascript:if(confirm('https://web.archive.org/web/20041107035721/http://www.thelancet.com/journal/vol364/iss9446/full/llan.364.9446.early_online_publication.31178.1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20041107035721/http://www.thelancet.com/journal/vol364/iss9446/full/llan.364.9446.early_online_publication.31178.1'" tppabs="https://web.archive.org/web/20041107035721/http://www.thelancet.com/journal/vol364/iss9446/full/llan.364.9446.early_online_publication.31178.1" class="external autonumber external"></a>  </span></li><li id="cite_note-Lancet_Implosion_Merck_2004-61"> <span id="mw-reference-text-cite_note-Lancet_Implosion_Merck_2004-61" class="mw-reference-text"><cite id="CITEREFHorton2004" class="citation journal cs1">Horton R (2004). "Vioxx, the implosion of Merck, and aftershocks at the FDA". <i>Lancet</i>. <b>364</b> (9450): 1995–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0140-6736%2804%2917523-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0140-6736%2804%2917523-5'" tppabs="https://doi.org/10.1016%2FS0140-6736%2804%2917523-5" class="external text external">10.1016/S0140-6736(04)17523-5</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15582041  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15582041'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15582041" class="external text external">15582041</a>.</cite></span></li><li id="cite_note-62"> <span id="mw-reference-text-cite_note-62" class="mw-reference-text">Merck &amp; Co., 2004</span></li><li id="cite_note-nothing_wrong-63"> <span id="mw-reference-text-cite_note-nothing_wrong-63" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('http://www.pharmexec.com/merck-did-nothing-wrong-martin-report-says  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pharmexec.com/merck-did-nothing-wrong-martin-report-says'" tppabs="http://www.pharmexec.com/merck-did-nothing-wrong-martin-report-says" class="external text external">"<span class="cs1-kern-left">'</span>Merck Did Nothing Wrong,' Martin Report says"</a>. Pharmaceutical Executive. Sep 13, 2006<span class="reference-accessdate">. Retrieved <span class="nowrap">27 January</span> 2019</span>.</cite></span></li><li id="cite_note-Martin_report_2006-64"> <span id="mw-reference-text-cite_note-Martin_report_2006-64" class="mw-reference-text"><cite id="CITEREFJohn_S._Martin_Jr.2006" class="citation report cs1">John S. Martin Jr. (September 5, 2006). Report of the Honorable Judge John S. Martin Jr. to the Special Committee of the Board of Directors of Merck &amp; Company, Inc concerning the conduct of senior management in the development and marketing of Vioxx. <i>Debevoise &amp; Plimpton LLP</i> (Report). p.<span>&nbsp;</span>183.</cite></span></li><li id="cite_note-65"> <span id="mw-reference-text-cite_note-65" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.news-medical.net/news/2005/07/11/11587.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.news-medical.net/news/2005/07/11/11587.aspx'" tppabs="https://www.news-medical.net/news/2005/07/11/11587.aspx" class="external text external">"Vioxx safe enough for Canadian market says health panel"</a>.</cite></span></li><li id="cite_note-66"> <span id="mw-reference-text-cite_note-66" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://money.cnn.com/2005/02/18/news/fortune500/merck/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://money.cnn.com/2005/02/18/news/fortune500/merck/'" tppabs="https://money.cnn.com/2005/02/18/news/fortune500/merck/" class="external text external">"FDA panel: Vioxx can return to market"</a>.</cite></span></li><li id="cite_note-67"> <span id="mw-reference-text-cite_note-67" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM106201.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM106201.pdf'" tppabs="https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM106201.pdf" class="external text external">"Analysis and recommendations for Agency action regarding nonsteroidal anti-inflammatory drugs and cardiovascular risk"</a> <span class="cs1-format">(PDF)</span>. <i>FDA</i>.</cite></span></li><li id="cite_note-Petryna_Experiments_Travel_2009-68"> <span id="mw-reference-text-cite_note-Petryna_Experiments_Travel_2009-68" class="mw-reference-text"><cite id="CITEREFPetryna2009" class="citation book cs1">Petryna A (2009). <a href="javascript:if(confirm('https://books.google.com/?id=cI6tAAAACAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/?id=cI6tAAAACAAJ'" tppabs="https://books.google.com/?id=cI6tAAAACAAJ" class="external text external"><i></i>When Experiments Travel:Clinical Trials and the Global Search for Human Subjects<i></i></a>. Princeton University Press. p.<span>&nbsp;</span>272. ISBN<span>&nbsp;</span><bdi>9780691126579</bdi>.</cite></span></li><li id="cite_note-69"> <span id="mw-reference-text-cite_note-69" class="mw-reference-text"><cite class="citation news cs1">Berenson A (13 April 2005). <a href="javascript:if(confirm('https://www.nytimes.com/2005/04/13/business/13drug.html?ex=1271044800&en=3225bb00e74eab08&ei=5090&partner=rssuserland  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2005/04/13/business/13drug.html?ex=1271044800&en=3225bb00e74eab08&ei=5090&partner=rssuserland'" tppabs="https://www.nytimes.com/2005/04/13/business/13drug.html?ex=1271044800&en=3225bb00e74eab08&ei=5090&partner=rssuserland" class="external text external">"Merck Asks for a Dismissal in First of Suits Over Vioxx"</a>. <i>The New York Times</i><span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-70"> <span id="mw-reference-text-cite_note-70" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.nbcnews.com/id/9006921  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nbcnews.com/id/9006921'" tppabs="http://www.nbcnews.com/id/9006921" class="external text external">"Jury finds Merck liable in landmark Vioxx case"</a>. <i>NBC News</i>. 20 August 2005<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-71"> <span id="mw-reference-text-cite_note-71" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.chron.com/business/article/Houston-court-rejects-Vioxx-death-link-26-1-1770637.php  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chron.com/business/article/Houston-court-rejects-Vioxx-death-link-26-1-1770637.php'" tppabs="http://www.chron.com/business/article/Houston-court-rejects-Vioxx-death-link-26-1-1770637.php" class="external text external">"Houston court rejects Vioxx-death link, $26.1 million award"</a>. <i>chron.com</i>. 2008-05-29<span class="reference-accessdate">. Retrieved <span class="nowrap">28 September</span> 2017</span>.</cite></span></li><li id="cite_note-72"> <span id="mw-reference-text-cite_note-72" class="mw-reference-text"><a href="javascript:if(confirm('https://www.npr.org/templates/story/story.php?storyId=4988532  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.npr.org/templates/story/story.php?storyId=4988532'" tppabs="https://www.npr.org/templates/story/story.php?storyId=4988532" class="external autonumber external"></a>  <a href="javascript:if(confirm('https://web.archive.org/web/20150921162135/http://www.npr.org/templates/story/story.php?storyId=4988532  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150921162135/http://www.npr.org/templates/story/story.php?storyId=4988532'" tppabs="https://web.archive.org/web/20150921162135/http://www.npr.org/templates/story/story.php?storyId=4988532" class="external text external">Archived</a><span> September 21, 2015, at the </span>Wayback Machine</span></li><li id="cite_note-NYT_Berenson_2005-73"> <span id="mw-reference-text-cite_note-NYT_Berenson_2005-73" class="mw-reference-text"><cite class="citation cs2">Berenson A (December 13, 2005), <a href="javascript:if(confirm('http://tech.mit.edu/V125/N61/61long4.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://tech.mit.edu/V125/N61/61long4.html'" tppabs="http://tech.mit.edu/V125/N61/61long4.html" class="external text external">"Judge Declares Mistrial in Merck Vioxx Trial Because of Hung Jury"</a>, <i>The New York Times</i><span class="reference-accessdate">, retrieved <span class="nowrap">December 24,</span> 2016</span></cite></span></li><li id="cite_note-74"> <span id="mw-reference-text-cite_note-74" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.bloomberg.com/apps/news?pid=20601087&sid=aVKMz77jAVo4&refer=home  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.bloomberg.com/apps/news?pid=20601087&sid=aVKMz77jAVo4&refer=home'" tppabs="https://www.bloomberg.com/apps/news?pid=20601087&sid=aVKMz77jAVo4&refer=home" class="external text external">"Merck Wins Reversal of Jury's $32 Million Vioxx Award (Update3)"</a>. Bloomberg.com<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-75"> <span id="mw-reference-text-cite_note-75" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('http://www.theage.com.au/national/drug-unfit-for-sale-says-judge-in-compo-case-20100305-powh.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.theage.com.au/national/drug-unfit-for-sale-says-judge-in-compo-case-20100305-powh.html'" tppabs="http://www.theage.com.au/national/drug-unfit-for-sale-says-judge-in-compo-case-20100305-powh.html" class="external text external">"Drug unfit for sale, says judge in compo case"</a>. <i>The Age</i>. Melbourne<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-NYT_Merck_2007-76"> <span id="mw-reference-text-cite_note-NYT_Merck_2007-76" class="mw-reference-text"><cite id="CITEREFBerensonnov2007" class="citation news cs1">Berensonnov A (November 9, 2007). <a href="javascript:if(confirm('https://www.nytimes.com/2007/11/09/business/09merck.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2007/11/09/business/09merck.html'" tppabs="https://www.nytimes.com/2007/11/09/business/09merck.html" class="external text external">"Merck Agrees to Settle Vioxx Suits for $4.85 Billion"</a>. <i>The New York Times</i><span class="reference-accessdate">. Retrieved <span class="nowrap">December 24,</span> 2016</span>.</cite></span></li><li id="cite_note-NYT_2008_Liptak-77"> <span id="mw-reference-text-cite_note-NYT_2008_Liptak-77" class="mw-reference-text"><cite id="CITEREFLiptak2008" class="citation news cs1">Liptak A (January 22, 2008). <a href="javascript:if(confirm('https://www.nytimes.com/2008/01/22/us/22bar.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2008/01/22/us/22bar.html'" tppabs="https://www.nytimes.com/2008/01/22/us/22bar.html" class="external text external">"In Vioxx Settlement, Testing a Legal Ideal: A Lawyer's Loyalty"</a>. <i>The New York Times</i><span class="reference-accessdate">. Retrieved <span class="nowrap">December 24,</span> 2016</span>.</cite></span></li><li id="cite_note-thenalfa.org-78"> <span id="mw-reference-text-cite_note-thenalfa.org-78" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.thenalfa.org/blog/$315m-fee-allocation-dispute-in-vioxx-class-action/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.thenalfa.org/blog/$315m-fee-allocation-dispute-in-vioxx-class-action/'" tppabs="http://www.thenalfa.org/blog/$315m-fee-allocation-dispute-in-vioxx-class-action/" class="external text external">"$315M Fee Allocation Dispure in Vioxx class actionThe NALFA"</a>. Thenalfa.org<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-79"> <span id="mw-reference-text-cite_note-79" class="mw-reference-text"><cite id="CITEREFDionne_Searcey2011" class="citation news cs1">Dionne Searcey (3 March 2011). <a href="javascript:if(confirm('https://blogs.wsj.com/law/2011/03/03/the-vioxx-endgame-its-all-about-the-fees/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://blogs.wsj.com/law/2011/03/03/the-vioxx-endgame-its-all-about-the-fees/'" tppabs="https://blogs.wsj.com/law/2011/03/03/the-vioxx-endgame-its-all-about-the-fees/" class="external text external">"The Vioxx Endgame: It's All About the Fees"</a>. <i>WSJ</i><span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-80"> <span id="mw-reference-text-cite_note-80" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('http://blogs.reuters.com/alison-frankel/2011/08/11/vioxx-judge-steps-in-to-split-350-ml-plaintiffs-lawyer-pie/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://blogs.reuters.com/alison-frankel/2011/08/11/vioxx-judge-steps-in-to-split-350-ml-plaintiffs-lawyer-pie/'" tppabs="http://blogs.reuters.com/alison-frankel/2011/08/11/vioxx-judge-steps-in-to-split-350-ml-plaintiffs-lawyer-pie/" class="external text external">"Vioxx judge steps in to split $350 ml plaintiffs lawyer pie"</a>. <i>Reuters</i>. 11 August 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-81"> <span id="mw-reference-text-cite_note-81" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.laed.uscourts.gov/vioxx/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.laed.uscourts.gov/vioxx/'" tppabs="http://www.laed.uscourts.gov/vioxx/" class="external text external">"Vioxx Product Liability"</a>. Laed.uscourts.gov<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-McClellan_2008-82"> <span id="mw-reference-text-cite_note-McClellan_2008-82" class="mw-reference-text"><cite id="CITEREFMcClellan2008" class="citation journal cs1">McClellan F (2008). "The Vioxx Litigation: A Critical Look at Trial Tactics, the Tort System, and the Roles of Lawyers in Mass Tort Litigation". <i>DePaul Law Review</i>. <b>57</b>: 509–38. SSRN<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://ssrn.com/abstract=1861337  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ssrn.com/abstract=1861337'" tppabs="https://ssrn.com/abstract=1861337" class="external text external">1861337</a></span>.</cite></span></li><li id="cite_note-83"> <span id="mw-reference-text-cite_note-83" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.insurancejournal.com/news/southcentral/2013/09/03/303718.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.insurancejournal.com/news/southcentral/2013/09/03/303718.htm'" tppabs="http://www.insurancejournal.com/news/southcentral/2013/09/03/303718.htm" class="external text external">"10 Years of Tort Reform in Texas Bring Fewer Suits, Lower Payouts"</a>. Insurancejournal.com. 3 September 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-84"> <span id="mw-reference-text-cite_note-84" class="mw-reference-text"><a href="javascript:if(confirm('http://www.merck.com/newsroom/news-release-archive/corporate/2011_1122.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.merck.com/newsroom/news-release-archive/corporate/2011_1122.html'" tppabs="http://www.merck.com/newsroom/news-release-archive/corporate/2011_1122.html" class="external autonumber external"></a>  <a href="javascript:if(confirm('https://web.archive.org/web/20111124205736/http://www.merck.com/newsroom/news-release-archive/corporate/2011_1122.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20111124205736/http://www.merck.com/newsroom/news-release-archive/corporate/2011_1122.html'" tppabs="https://web.archive.org/web/20111124205736/http://www.merck.com/newsroom/news-release-archive/corporate/2011_1122.html" class="external text external">Archived</a><span> November 24, 2011, at the </span>Wayback Machine</span></li><li id="cite_note-85"> <span id="mw-reference-text-cite_note-85" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.reuters.com/article/2011/11/22/us-doj-merck-idUSTRE7AL2C120111122  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.reuters.com/article/2011/11/22/us-doj-merck-idUSTRE7AL2C120111122'" tppabs="https://www.reuters.com/article/2011/11/22/us-doj-merck-idUSTRE7AL2C120111122" class="external text external">"Merck to pay $950 million to settle U.S. Vioxx charge"</a>. <i>Reuters</i>. 22 November 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">4 January</span> 2015</span>.</cite></span></li><li id="cite_note-86"> <span id="mw-reference-text-cite_note-86" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.tremeaurx.com/news/2019/3/8/tremeau-expands-leadership-team  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.tremeaurx.com/news/2019/3/8/tremeau-expands-leadership-team'" tppabs="https://www.tremeaurx.com/news/2019/3/8/tremeau-expands-leadership-team" class="external text external">"Tremeau Expands Leadership Team"</a>.</cite></span></li><li id="cite_note-87"> <span id="mw-reference-text-cite_note-87" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.tremeaurx.com/news/2019/3/29/tremeau-to-exhibit-at-htrs-in-may  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.tremeaurx.com/news/2019/3/29/tremeau-to-exhibit-at-htrs-in-may'" tppabs="https://www.tremeaurx.com/news/2019/3/29/tremeau-to-exhibit-at-htrs-in-may" class="external text external">"Tremeau to Exhibit at HTRS in May"</a>.</cite></span></li></ol></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<style data-mw-deduplicate="TemplateStyles:r886047268">.mw-parser-output .refbegin{font-size:90%;margin-bottom:0.5em}.mw-parser-output .refbegin-hanging-indents>ul{list-style-type:none;margin-left:0}.mw-parser-output .refbegin-hanging-indents>ul>li,.mw-parser-output .refbegin-hanging-indents>dl>dd{margin-left:0;padding-left:3.2em;text-indent:-3.2em;list-style:none}.mw-parser-output .refbegin-100{font-size:100%}</style><div class="refbegin reflist   " style="">
<ul><li>FDA (2005). "Summary minutes for the February 16, 17 and 18, 2005, Joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee." Published on the internet, March 2005. <a href="javascript:if(confirm('https://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4090M1_Final.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4090M1_Final.htm'" tppabs="https://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4090M1_Final.htm" class="external text external">Link</a></li>
<li><cite id="CITEREFFitzgerald2004" class="citation journal cs1">Fitzgerald GA (October 2004). "Coxibs and cardiovascular disease". <i>The New England Journal of Medicine</i>. <b>351</b> (17): 1709–11. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMp048288  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMp048288'" tppabs="https://doi.org/10.1056%2FNEJMp048288" class="external text external">10.1056/NEJMp048288</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15470192  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15470192'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15470192" class="external text external">15470192</a>.</cite></li>
<li>Grassley CE (15 Oct 2004). <i><a href="javascript:if(confirm('https://web.archive.org/web/20041029135457/http://finance.senate.gov/press/Gpress/2004/prg101504.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20041029135457/http://finance.senate.gov/press/Gpress/2004/prg101504.pdf'" tppabs="https://web.archive.org/web/20041029135457/http://finance.senate.gov/press/Gpress/2004/prg101504.pdf" class="external text external">Grassley questions Merck about communication with the FDA on Vioxx.</a></i> Press Release.</li>
<li><cite id="CITEREFJüniNarteyReichenbachSterchi2004" class="citation journal cs1">Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004). "Risk of cardiovascular events and rofecoxib: cumulative meta-analysis". <i>Lancet</i>. <b>364</b> (9450): 2021–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0140-6736%2804%2917514-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0140-6736%2804%2917514-4'" tppabs="https://doi.org/10.1016%2FS0140-6736%2804%2917514-4" class="external text external">10.1016/S0140-6736(04)17514-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15582059  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15582059'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15582059" class="external text external">15582059</a>.</cite></li>
<li><cite id="CITEREFKarhaTopol2004" class="citation journal cs1">Karha J, Topol EJ (December 2004). <a href="javascript:if(confirm('https://semanticscholar.org/paper/804d74b9ae23c4538e1228e43e7df06a1cfc4647  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://semanticscholar.org/paper/804d74b9ae23c4538e1228e43e7df06a1cfc4647'" tppabs="https://semanticscholar.org/paper/804d74b9ae23c4538e1228e43e7df06a1cfc4647" class="external text external">"The sad story of Vioxx, and what we should learn from it"</a>. <i>Cleveland Clinic Journal of Medicine</i>. <b>71</b> (12): 933–4, 936, 938–9. doi:<a href="javascript:if(confirm('https://doi.org/10.3949%2Fccjm.71.12.933  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3949%2Fccjm.71.12.933'" tppabs="https://doi.org/10.3949%2Fccjm.71.12.933" class="external text external">10.3949/ccjm.71.12.933</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15641522  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15641522'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15641522" class="external text external">15641522</a>.</cite></li>
<li><cite id="CITEREFMichaels2005" class="citation journal cs1">Michaels, David (June 2005). "Doubt is their Product". <i>Scientific American</i>. <b>292</b> (6): 96–101. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2005SciAm.292f..96M  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2005SciAm.292f..96M'" tppabs="https://ui.adsabs.harvard.edu/abs/2005SciAm.292f..96M" class="external text external">2005SciAm.292f..96M</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fscientificamerican0605-96  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fscientificamerican0605-96'" tppabs="https://doi.org/10.1038%2Fscientificamerican0605-96" class="external text external">10.1038/scientificamerican0605-96</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15934658  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15934658'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15934658" class="external text external">15934658</a>.</cite></li>
<li>Merck &amp; Co., (5 Nov 2004). <i><a href="javascript:if(confirm('https://web.archive.org/web/20041221215942/http://www.merck.com/statement_2004_1105/lancet.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20041221215942/http://www.merck.com/statement_2004_1105/lancet.pdf'" tppabs="https://web.archive.org/web/20041221215942/http://www.merck.com/statement_2004_1105/lancet.pdf" class="external text external">Response to Article by Juni et al. Published in The Lancet on Nov. 5.</a></i> Press Release.</li>
<li>Merck &amp; Co (30 Sep 2004) Merck Announces Voluntary Worldwide Withdrawal of VIOXX. Press release <a href="javascript:if(confirm('https://web.archive.org/web/20050118105613/http://vioxx.com/vioxx/documents/english/vioxx_press_release.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20050118105613/http://vioxx.com/vioxx/documents/english/vioxx_press_release.pdf'" tppabs="https://web.archive.org/web/20050118105613/http://vioxx.com/vioxx/documents/english/vioxx_press_release.pdf" class="external autonumber external"></a>.</li>
<li><cite id="CITEREFMukherjeeNissenTopol2001" class="citation journal cs1">Mukherjee D, Nissen SE, Topol EJ (2001). <a href="javascript:if(confirm('https://semanticscholar.org/paper/7a377f62af8909f715570b30a16de2ffdb5210f3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://semanticscholar.org/paper/7a377f62af8909f715570b30a16de2ffdb5210f3'" tppabs="https://semanticscholar.org/paper/7a377f62af8909f715570b30a16de2ffdb5210f3" class="external text external">"Risk of cardiovascular events associated with selective COX-2 inhibitors"</a>. <i>JAMA</i>. <b>286</b> (8): 954–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1001%2Fjama.286.8.954  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjama.286.8.954'" tppabs="https://doi.org/10.1001%2Fjama.286.8.954" class="external text external">10.1001/jama.286.8.954</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11509060  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11509060'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11509060" class="external text external">11509060</a>.</cite></li>
<li><cite id="CITEREFNussmeierWheltonBrownLangford2005" class="citation journal cs1">Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM (March 2005). <a href="javascript:if(confirm('https://semanticscholar.org/paper/bbd6cd190a0b322488d75cbd2da97c2626a4e8f6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://semanticscholar.org/paper/bbd6cd190a0b322488d75cbd2da97c2626a4e8f6'" tppabs="https://semanticscholar.org/paper/bbd6cd190a0b322488d75cbd2da97c2626a4e8f6" class="external text external">"Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery"</a>. <i>The New England Journal of Medicine</i>. <b>352</b> (11): 1081–91. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa050330  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa050330'" tppabs="https://doi.org/10.1056%2FNEJMoa050330" class="external text external">10.1056/NEJMoa050330</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15713945  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15713945'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15713945" class="external text external">15713945</a>.</cite></li>
<li><cite id="CITEREFOkie2005" class="citation journal cs1">Okie S (March 2005). "Raising the safety bar--the FDA's coxib meeting". <i>The New England Journal of Medicine</i>. <b>352</b> (13): 1283–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMp058055  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMp058055'" tppabs="https://doi.org/10.1056%2FNEJMp058055" class="external text external">10.1056/NEJMp058055</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15800221  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15800221'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15800221" class="external text external">15800221</a>.</cite></li>
<li><cite id="CITEREFReddyCorey2005" class="citation journal cs1">Reddy, Leleti Rajender; Corey, E.J. (2005). "Facile air oxidation of the conjugate base of rofecoxib (Vioxx™), a possible contributor to chronic human toxicity". <i>Tetrahedron Letters</i>. <b>46</b> (6): 927–929. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.tetlet.2004.12.055  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.tetlet.2004.12.055'" tppabs="https://doi.org/10.1016%2Fj.tetlet.2004.12.055" class="external text external">10.1016/j.tetlet.2004.12.055</a>.</cite></li>
<li><cite id="CITEREFSwanRudyLasseterRyan2000" class="citation journal cs1">Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ, Gumbs CP, Ebel DL, Quan H, Larson PJ, Schwartz JI, Musliner TA, Gertz BJ, Brater DC, Yao SL (July 2000). "Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial". <i>Annals of Internal Medicine</i>. <b>133</b> (1): 1–9. doi:<a href="javascript:if(confirm('https://doi.org/10.7326%2F0003-4819-133-1-200007040-00002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.7326%2F0003-4819-133-1-200007040-00002'" tppabs="https://doi.org/10.7326%2F0003-4819-133-1-200007040-00002" class="external text external">10.7326/0003-4819-133-1-200007040-00002</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10877734  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10877734'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10877734" class="external text external">10877734</a>.</cite></li>
<li>Targum, SL. (1 Feb. 2001) Review of cardiovascular safety database. <i>FDA memorandum.</i> <a href="javascript:if(confirm('https://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf'" tppabs="https://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf" class="external autonumber external"></a></li>
<li><cite id="CITEREFWolfeLichtensteinSingh1999" class="citation journal cs1">Wolfe MM, Lichtenstein DR, Singh G (June 1999). "Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs". <i>The New England Journal of Medicine</i>. <b>340</b> (24): 1888–99. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJM199906173402407  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJM199906173402407'" tppabs="https://doi.org/10.1056%2FNEJM199906173402407" class="external text external">10.1056/NEJM199906173402407</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10369853  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10369853'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10369853" class="external text external">10369853</a>.</cite></li>
<li><cite id="CITEREFThe_Lancet2004" class="citation journal cs1">The Lancet (2004). "Vioxx: an unequal partnership between safety and efficacy". <i>Lancet</i>. <b>364</b> (9442): 1287–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0140-6736%2804%2917198-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0140-6736%2804%2917198-5'" tppabs="https://doi.org/10.1016%2FS0140-6736%2804%2917198-5" class="external text external">10.1016/S0140-6736(04)17198-5</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15474114  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15474114'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15474114" class="external text external">15474114</a>.</cite></li></ul>
</div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    

<ul><li><a href="javascript:if(confirm('https://web.archive.org/web/20070103071954/http://www.courttv.com/trials/vioxx/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20070103071954/http://www.courttv.com/trials/vioxx/'" tppabs="https://web.archive.org/web/20070103071954/http://www.courttv.com/trials/vioxx/" class="external text external">Court TV's full coverage of the Vioxx civil trials</a></li>
<li><a href="javascript:if(confirm('https://web.archive.org/web/20060822003656/http://www.learnaboutvioxx.com/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20060822003656/http://www.learnaboutvioxx.com/'" tppabs="https://web.archive.org/web/20060822003656/http://www.learnaboutvioxx.com/" class="external text external">Merck website on Vioxx litigation</a></li>
<li><a href="javascript:if(confirm('https://www.fda.gov/cder/drug/infopage/vioxx/PHA_vioxx.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/cder/drug/infopage/vioxx/PHA_vioxx.htm'" tppabs="https://www.fda.gov/cder/drug/infopage/vioxx/PHA_vioxx.htm" class="external text external">FDA Public Health Advisory on Vioxx</a></li>
<li>David Michaels. <i><a href="javascript:if(confirm('https://web.archive.org/web/20060218185546/http://www.sciamdigital.com/browse.cfm?sequencenameCHAR=item2&methodnameCHAR=resource_getitembrowse&interfacenameCHAR=browse.cfm&ISSUEID_CHAR=B38CE21A-2B35-221B-67096ED4BD9F95F7&ARTICLEID_CHAR=B3AF7D6A-2B35-221B-601840861CEDAFE1&sc=I100322  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20060218185546/http://www.sciamdigital.com/browse.cfm?sequencenameCHAR=item2&methodnameCHAR=resource_getitembrowse&interfacenameCHAR=browse.cfm&ISSUEID_CHAR=B38CE21A-2B35-221B-67096ED4BD9F95F7&ARTICLEID_CHAR=B3AF7D6A-2B35-221B-601840861CEDAFE1&sc=I100322'" tppabs="https://web.archive.org/web/20060218185546/http://www.sciamdigital.com/browse.cfm?sequencenameCHAR=item2&methodnameCHAR=resource_getitembrowse&interfacenameCHAR=browse.cfm&ISSUEID_CHAR=B38CE21A-2B35-221B-67096ED4BD9F95F7&ARTICLEID_CHAR=B3AF7D6A-2B35-221B-601840861CEDAFE1&sc=I100322" class="external text external">Doubt is Their Product</a></i> Scientific American, June 2004, p.<span>&nbsp;</span>96-101</li>
<li>JURIST, <a href="javascript:if(confirm('https://web.archive.org/web/20060127064619/http://jurist.law.pitt.edu/forumy/2006/01/much-pain-much-gain-skeptical.php  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20060127064619/http://jurist.law.pitt.edu/forumy/2006/01/much-pain-much-gain-skeptical.php'" tppabs="https://web.archive.org/web/20060127064619/http://jurist.law.pitt.edu/forumy/2006/01/much-pain-much-gain-skeptical.php" class="external text external">Much Pain, Much Gain: Skeptical Ruminations on the Vioxx Litigation</a></li>
<li>Ted Frank, American Enterprise Institute, <i>The Vioxx Litigation</i>, <a href="javascript:if(confirm('https://web.archive.org/web/20060119225517/http://www.aei.org/research/liability/publications/pubID.23513%2CprojectID.23/pub_detail.asp  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20060119225517/http://www.aei.org/research/liability/publications/pubID.23513%2CprojectID.23/pub_detail.asp'" tppabs="https://web.archive.org/web/20060119225517/http://www.aei.org/research/liability/publications/pubID.23513%2CprojectID.23/pub_detail.asp" class="external text external">Part I</a> and <a href="javascript:if(confirm('https://web.archive.org/web/20060119225606/http://www.aei.org/research/liability/publications/pubID.23542%2CprojectID.23/pub_detail.asp  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20060119225606/http://www.aei.org/research/liability/publications/pubID.23542%2CprojectID.23/pub_detail.asp'" tppabs="https://web.archive.org/web/20060119225606/http://www.aei.org/research/liability/publications/pubID.23542%2CprojectID.23/pub_detail.asp" class="external text external">Part II</a>, December 2005</li>
<li><a href="javascript:if(confirm('http://briandeer.com/rofecoxib-index.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://briandeer.com/rofecoxib-index.htm'" tppabs="http://briandeer.com/rofecoxib-index.htm" class="external text external">briandeer.com - Vioxx: the UK connection</a></li>
<li><a href="javascript:if(confirm('https://web.archive.org/web/20081119142016/http://www.vioxxvictims.co.uk/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20081119142016/http://www.vioxxvictims.co.uk/'" tppabs="https://web.archive.org/web/20081119142016/http://www.vioxxvictims.co.uk/" class="external text external">Campaign for compensation for Vioxx victims outside the US</a></li>
<li>Ron Unz, The Unz Review: An Alternative Media Selection, <i><a href="javascript:if(confirm('http://www.unz.com/article/chinese-melamine-and-american-vioxx-a-comparison/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.unz.com/article/chinese-melamine-and-american-vioxx-a-comparison/'" tppabs="http://www.unz.com/article/chinese-melamine-and-american-vioxx-a-comparison/" class="external text external">Chinese Melamine and American Vioxx: A Comparison</a></i></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Nonsteroidal_anti-inflammatory_drugs_(NSAIDs)_(primarily_M01A_and_M02A,_also_N02BA)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Nonsteroidal_anti-inflammatory_drugs_(NSAIDs)_(primarily_M01A_and_M02A,_also_N02BA)" style="font-size:114%;margin:0 4em">Nonsteroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Pyrazolones / <br><a href="Pyrazolidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pyrazolidine" title="Pyrazolidine">Pyrazolidines</a></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Aminophenazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminophenazone" title="Aminophenazone">Aminophenazone</a></li>
<li><a href="Ampyrone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ampyrone" title="Ampyrone">Ampyrone</a></li>
<li>Azapropazone</li>
<li>Clofezone</li>
<li>Difenamizole</li>
<li>Famprofazone</li>
<li>Feprazone</li>
<li>Kebuzone</li>
<li><a href="Metamizole.htm" tppabs="https://ptable.com/wiki/compounds/A/Metamizole" title="Metamizole">Metamizole</a></li>
<li>Mofebutazone</li>
<li>Morazone</li>
<li><a href="Nifenazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Nifenazone" title="Nifenazone">Nifenazone</a></li>
<li><a href="Oxyphenbutazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxyphenbutazone" title="Oxyphenbutazone">Oxyphenbutazone</a></li>
<li><a href="Phenazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenazone" title="Phenazone">Phenazone</a></li>
<li><b><a href="Phenylbutazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylbutazone" title="Phenylbutazone">Phenylbutazone</a></b></li>
<li>Propyphenazone</li>
<li><a href="Sulfinpyrazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulfinpyrazone" title="Sulfinpyrazone">Sulfinpyrazone</a></li>
<li><a href="Suxibuzone.htm" tppabs="https://ptable.com/wiki/compounds/A/Suxibuzone" title="Suxibuzone">Suxibuzone</a><sup>‡</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Salicylic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicylic_acid" title="Salicylic acid">Salicylates</a></th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b><a href="Aspirin.htm" tppabs="https://ptable.com/wiki/compounds/A/Aspirin" title="Aspirin">Aspirin (acetylsalicylic acid)</a></b><sup>#</sup></li>
<li>Aloxiprin</li>
<li>Benorylate</li>
<li>Carbasalate calcium</li>
<li><a href="Diflunisal.htm" tppabs="https://ptable.com/wiki/compounds/A/Diflunisal" title="Diflunisal">Diflunisal</a></li>
<li>Dipyrocetyl</li>
<li><a href="Ethenzamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethenzamide" title="Ethenzamide">Ethenzamide</a></li>
<li>Guacetisal</li>
<li>Magnesium salicylate</li>
<li><a href="Methyl_salicylate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyl_salicylate" title="Methyl salicylate">Methyl salicylate</a></li>
<li><a href="Salsalate.htm" tppabs="https://ptable.com/wiki/compounds/A/Salsalate" title="Salsalate">Salsalate</a></li>
<li><a href="Salicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicin" title="Salicin">Salicin</a></li>
<li><a href="Salicylamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicylamide" title="Salicylamide">Salicylamide</a></li>
<li><a href="Salicylic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicylic_acid" title="Salicylic acid">Salicylic acid (salicylate)</a></li>
<li><a href="Sodium_salicylate.htm" tppabs="https://ptable.com/wiki/compounds/A/Sodium_salicylate" title="Sodium salicylate">Sodium salicylate</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Acetic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Acetic_acid" title="Acetic acid">Acetic acid</a> derivatives<br>and related substances</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Aceclofenac</li>
<li><a href="Acemetacin.htm" tppabs="https://ptable.com/wiki/compounds/A/Acemetacin" title="Acemetacin">Acemetacin</a></li>
<li>Alclofenac</li>
<li>Amfenac</li>
<li>Bendazac</li>
<li><a href="Bromfenac.htm" tppabs="https://ptable.com/wiki/compounds/A/Bromfenac" title="Bromfenac">Bromfenac</a></li>
<li>Bumadizone</li>
<li><a href="Bufexamac.htm" tppabs="https://ptable.com/wiki/compounds/A/Bufexamac" title="Bufexamac">Bufexamac</a></li>
<li><b><a href="Diclofenac.htm" tppabs="https://ptable.com/wiki/compounds/A/Diclofenac" title="Diclofenac">Diclofenac</a></b></li>
<li>Difenpiramide</li>
<li><a href="Etodolac.htm" tppabs="https://ptable.com/wiki/compounds/A/Etodolac" title="Etodolac">Etodolac</a></li>
<li><a href="Felbinac.htm" tppabs="https://ptable.com/wiki/compounds/A/Felbinac" title="Felbinac">Felbinac</a></li>
<li>Fenclozic acid</li>
<li>Fentiazac</li>
<li><a href="Indometacin.htm" tppabs="https://ptable.com/wiki/compounds/A/Indometacin" title="Indometacin">Indometacin</a></li>
<li>Indometacin farnesil</li>
<li><span class="new">Isoxepac</span></li>
<li><a href="Ketorolac.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketorolac" title="Ketorolac">Ketorolac</a></li>
<li>Lonazolac</li>
<li>Oxametacin</li>
<li><span class="new">Prodolic acid</span></li>
<li>Proglumetacin</li>
<li><a href="Sulindac.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulindac" title="Sulindac">Sulindac</a></li>
<li><span class="new">Tiopinac</span></li>
<li><a href="Tolmetin.htm" tppabs="https://ptable.com/wiki/compounds/A/Tolmetin" title="Tolmetin">Tolmetin</a></li>
<li><a href="Zomepirac.htm" tppabs="https://ptable.com/wiki/compounds/A/Zomepirac" title="Zomepirac">Zomepirac</a><sup>†</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Oxicams</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Ampiroxicam</li>
<li>Droxicam</li>
<li>Isoxicam</li>
<li>Lornoxicam</li>
<li><a href="Meloxicam.htm" tppabs="https://ptable.com/wiki/compounds/A/Meloxicam" title="Meloxicam">Meloxicam</a></li>
<li><b><a href="Piroxicam.htm" tppabs="https://ptable.com/wiki/compounds/A/Piroxicam" title="Piroxicam">Piroxicam</a></b></li>
<li><a href="Tenoxicam.htm" tppabs="https://ptable.com/wiki/compounds/A/Tenoxicam" title="Tenoxicam">Tenoxicam</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Propionic acid derivatives<br>(profens)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Alminoprofen</li>
<li><a href="Benoxaprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Benoxaprofen" title="Benoxaprofen">Benoxaprofen</a><sup>†</sup></li>
<li><a href="Carprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Carprofen" title="Carprofen">Carprofen</a><sup>‡</sup></li>
<li>Dexibuprofen</li>
<li>Dexketoprofen</li>
<li><a href="Fenbufen.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenbufen" title="Fenbufen">Fenbufen</a></li>
<li><a href="Fenoprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenoprofen" title="Fenoprofen">Fenoprofen</a></li>
<li>Flunoxaprofen</li>
<li><a href="Flurbiprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Flurbiprofen" title="Flurbiprofen">Flurbiprofen</a></li>
<li><b><a href="Ibuprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibuprofen" title="Ibuprofen">Ibuprofen</a></b><sup>#</sup></li>
<li>Ibuproxam</li>
<li><a href="Indoprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Indoprofen" title="Indoprofen">Indoprofen</a><sup>†</sup></li>
<li><a href="Ketoprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoprofen" title="Ketoprofen">Ketoprofen</a></li>
<li>Loxoprofen</li>
<li>Miroprofen</li>
<li><b><a href="Naproxen.htm" tppabs="https://ptable.com/wiki/compounds/A/Naproxen" title="Naproxen">Naproxen</a></b></li>
<li><a href="Oxaprozin.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxaprozin" title="Oxaprozin">Oxaprozin</a></li>
<li>Pirprofen</li>
<li><a href="Suprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Suprofen" title="Suprofen">Suprofen</a></li>
<li>Tarenflurbil</li>
<li>Tepoxalin<sup>‡</sup></li>
<li><a href="Tiaprofenic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Tiaprofenic_acid" title="Tiaprofenic acid">Tiaprofenic acid</a></li>
<li>Vedaprofen<sup>‡</sup></li>
<li>Zaltoprofen</li>
<li><i>COX-inhibiting nitric oxide donator</i>: Naproxcinod</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><i>N</i>-Arylanthranilic acids<br>(<a href="Fenamic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenamate" title="Fenamate" class="mw-redirect">fenamates</a>)</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Azapropazone</li>
<li>Clonixin</li>
<li>Etofenamate</li>
<li><a href="Flufenamic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Flufenamic_acid" title="Flufenamic acid">Flufenamic acid</a></li>
<li><a href="Flunixin.htm" tppabs="https://ptable.com/wiki/compounds/A/Flunixin" title="Flunixin">Flunixin</a></li>
<li><a href="Meclofenamic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Meclofenamic_acid" title="Meclofenamic acid">Meclofenamic acid</a></li>
<li><b><a href="Mefenamic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Mefenamic_acid" title="Mefenamic acid">Mefenamic acid</a></b></li>
<li>Morniflumate</li>
<li><a href="Niflumic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Niflumic_acid" title="Niflumic acid">Niflumic acid</a></li>
<li><a href="Tolfenamic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Tolfenamic_acid" title="Tolfenamic acid">Tolfenamic acid</a></li>
<li><span class="new">Flutiazin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Coxibs</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Apricoxib</li>
<li><b><a href="Celecoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Celecoxib" title="Celecoxib">Celecoxib</a></b></li>
<li>Cimicoxib<sup>‡</sup></li>
<li>Deracoxib<sup>‡</sup></li>
<li><a href="Etoricoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Etoricoxib" title="Etoricoxib">Etoricoxib</a></li>
<li>Firocoxib<sup>‡</sup></li>
<li><a href="Lumiracoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lumiracoxib" title="Lumiracoxib">Lumiracoxib</a><sup>†</sup></li>
<li>Mavacoxib<sup>‡</sup></li>
<li>Parecoxib</li>
<li>Robenacoxib<sup>‡</sup></li>
<li><a href="Rofecoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Rofecoxib" title="Rofecoxib">Rofecoxib</a><sup>†</sup></li>
<li><a href="Valdecoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Valdecoxib" title="Valdecoxib">Valdecoxib</a><sup>†</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Aminopropionitrile.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminopropionitrile" title="Aminopropionitrile">Aminopropionitrile</a></li>
<li>Benzydamine</li>
<li><a href="Chondroitin_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Chondroitin_sulfate" title="Chondroitin sulfate">Chondroitin sulfate</a></li>
<li><a href="Diacerein.htm" tppabs="https://ptable.com/wiki/compounds/A/Diacerein" title="Diacerein">Diacerein</a></li>
<li>Fluproquazone</li>
<li><a href="Glucosamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Glucosamine" title="Glucosamine">Glucosamine</a></li>
<li>Glycosaminoglycan</li>
<li><a href="Hyperforin.htm" tppabs="https://ptable.com/wiki/compounds/A/Hyperforin" title="Hyperforin">Hyperforin</a></li>
<li><a href="Nabumetone.htm" tppabs="https://ptable.com/wiki/compounds/A/Nabumetone" title="Nabumetone">Nabumetone</a></li>
<li><a href="Nimesulide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nimesulide" title="Nimesulide">Nimesulide</a></li>
<li><a href="Oxaceprol.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxaceprol" title="Oxaceprol">Oxaceprol</a></li>
<li>Proquazone</li>
<li>Superoxide dismutase/Orgotein</li>
<li>Tenidap</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd hlist" style="width:100%;padding:0px"><div style="padding:0em 0.25em">Items listed in <b>bold</b> indicate initially developed compounds of specific groups. <sup>#</sup>WHO-EM <sup>†</sup>Withdrawn drugs. <sup>‡</sup>Veterinary use medications.</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Analgesics_(N02A,_N02B)" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Analgesics_(N02A,_N02B)" style="font-size:114%;margin:0 4em">Analgesics (N02A, N02B)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Opioids</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Opiates/opium</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width: auto;"><div style="padding:0em 0.25em">
<ul><li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Codeine  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Codeine'" tppabs="https://ptable.com/wiki/compounds/A/Codeine" title="Codeine">Codeine</a><sup>#</sup> (+paracetamol, +aspirin)</li>
<li><a href="Morphine.htm" tppabs="https://ptable.com/wiki/compounds/A/Morphine" title="Morphine">Morphine</a><sup>#</sup> (+naltrexone)</li>
<li>Opium</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Laudanum  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Laudanum'" tppabs="https://ptable.com/wiki/compounds/A/Laudanum" title="Laudanum">Laudanum</a></li>
<li>Paregoric</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Semisynthetic</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width: auto;"><div style="padding:0em 0.25em">
<ul><li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Acetyldihydrocodeine  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Acetyldihydrocodeine'" tppabs="https://ptable.com/wiki/compounds/A/Acetyldihydrocodeine" title="Acetyldihydrocodeine">Acetyldihydrocodeine</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Benzylmorphine  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Benzylmorphine'" tppabs="https://ptable.com/wiki/compounds/A/Benzylmorphine" title="Benzylmorphine">Benzylmorphine</a></li>
<li><a href="Buprenorphine.htm" tppabs="https://ptable.com/wiki/compounds/A/Buprenorphine" title="Buprenorphine">Buprenorphine</a> (+naloxone)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Desomorphine  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Desomorphine'" tppabs="https://ptable.com/wiki/compounds/A/Desomorphine" title="Desomorphine">Desomorphine</a></li>
<li><a href="Heroin.htm" tppabs="https://ptable.com/wiki/compounds/A/Heroin" title="Heroin">Diamorphine (heroin)</a></li>
<li><a href="Dihydrocodeine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrocodeine" title="Dihydrocodeine">Dihydrocodeine</a> (+paracetamol)</li>
<li><a href="Dihydromorphine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydromorphine" title="Dihydromorphine">Dihydromorphine</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Ethylmorphine  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Ethylmorphine'" tppabs="https://ptable.com/wiki/compounds/A/Ethylmorphine" title="Ethylmorphine">Ethylmorphine</a></li>
<li><a href="Hydrocodone.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydrocodone" title="Hydrocodone">Hydrocodone</a> (+paracetamol, +ibuprofen, +aspirin)</li>
<li><a href="Hydromorphinol.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydromorphinol" title="Hydromorphinol">Hydromorphinol</a></li>
<li><a href="Hydromorphone.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydromorphone" title="Hydromorphone">Hydromorphone</a></li>
<li>Nicocodeine</li>
<li>Nicodicodine</li>
<li>Nicomorphine</li>
<li><a href="Oxycodone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxycodone" title="Oxycodone">Oxycodone</a> (+paracetamol, +aspirin, +ibuprofen, +naloxone, <span class="new">+naltrexone</span>)</li>
<li><a href="Oxymorphone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxymorphone" title="Oxymorphone">Oxymorphone</a></li>
<li>Thebacon</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Synthetic</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width: auto;"><div style="padding:0em 0.25em">
<ul><li><a href="Alfentanil.htm" tppabs="https://ptable.com/wiki/compounds/A/Alfentanil" title="Alfentanil">Alfentanil</a></li>
<li><a href="Prodine.htm" tppabs="https://ptable.com/wiki/compounds/A/Prodine" title="Prodine">Alphaprodine</a></li>
<li><a href="Anileridine.htm" tppabs="https://ptable.com/wiki/compounds/A/Anileridine" title="Anileridine">Anileridine</a></li>
<li><a href="Butorphanol.htm" tppabs="https://ptable.com/wiki/compounds/A/Butorphanol" title="Butorphanol">Butorphanol</a></li>
<li><a href="Carfentanil.htm" tppabs="https://ptable.com/wiki/compounds/A/Carfentanil" title="Carfentanil">Carfentanil</a></li>
<li><a href="Dextromoramide.htm" tppabs="https://ptable.com/wiki/compounds/A/Dextromoramide" title="Dextromoramide">Dextromoramide</a></li>
<li><a href="Dextropropoxyphene.htm" tppabs="https://ptable.com/wiki/compounds/A/Dextropropoxyphene" title="Dextropropoxyphene">Dextropropoxyphene</a></li>
<li><a href="Dezocine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dezocine" title="Dezocine">Dezocine</a></li>
<li><a href="Dipipanone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dipipanone" title="Dipipanone">Dipipanone</a></li>
<li><a href="Fentanyl.htm" tppabs="https://ptable.com/wiki/compounds/A/Fentanyl" title="Fentanyl">Fentanyl</a><sup>#</sup> (+fluanisone)</li>
<li>Ketobemidone</li>
<li><a href="Levorphanol.htm" tppabs="https://ptable.com/wiki/compounds/A/Levorphanol" title="Levorphanol">Levorphanol</a></li>
<li>Lofentanil</li>
<li>Meptazinol</li>
<li><a href="Methadone.htm" tppabs="https://ptable.com/wiki/compounds/A/Methadone" title="Methadone">Methadone</a><sup>#</sup></li>
<li><a href="Nalbuphine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nalbuphine" title="Nalbuphine">Nalbuphine</a></li>
<li>NFEPP</li>
<li><a href="Pentazocine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pentazocine" title="Pentazocine">Pentazocine</a></li>
<li><a href="Pethidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pethidine" title="Pethidine">Pethidine (meperidine)</a></li>
<li>Phenadoxone</li>
<li>Phenazocine</li>
<li>Piminodine</li>
<li>Piritramide</li>
<li>Propiram</li>
<li><a href="Remifentanil.htm" tppabs="https://ptable.com/wiki/compounds/A/Remifentanil" title="Remifentanil">Remifentanil</a></li>
<li><a href="Sufentanil.htm" tppabs="https://ptable.com/wiki/compounds/A/Sufentanil" title="Sufentanil">Sufentanil</a></li>
<li>Tapentadol</li>
<li>Tilidine</li>
<li><a href="Tramadol.htm" tppabs="https://ptable.com/wiki/compounds/A/Tramadol" title="Tramadol">Tramadol</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Paracetamol.htm" tppabs="https://ptable.com/wiki/compounds/A/Paracetamol" title="Paracetamol">Paracetamol</a>-type</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Acetanilide.htm" tppabs="https://ptable.com/wiki/compounds/A/Acetanilide" title="Acetanilide">Acetanilide</a><sup>‡</sup></li>
<li><a href="Bucetin.htm" tppabs="https://ptable.com/wiki/compounds/A/Bucetin" title="Bucetin">Bucetin</a><sup>‡</sup></li>
<li><span class="new">Butacetin</span><sup>‡</sup></li>
<li><a href="Paracetamol.htm" tppabs="https://ptable.com/wiki/compounds/A/Paracetamol" title="Paracetamol">Paracetamol (acetaminophen)</a><sup>#</sup></li>
<li><span class="new">Parapropamol</span><sup>‡</sup></li>
<li><a href="Phenacetin.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenacetin" title="Phenacetin">Phenacetin</a><sup>‡</sup></li>
<li>Propacetamol<sup>‡</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">NSAIDs</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Propionates</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width: auto;"><div style="padding:0em 0.25em">
<ul><li><a href="Fenoprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenoprofen" title="Fenoprofen">Fenoprofen</a></li>
<li><a href="Flurbiprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Flurbiprofen" title="Flurbiprofen">Flurbiprofen</a></li>
<li><a href="Ibuprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibuprofen" title="Ibuprofen">Ibuprofen</a><sup>#</sup></li>
<li><a href="Ketoprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoprofen" title="Ketoprofen">Ketoprofen</a></li>
<li><a href="Naproxen.htm" tppabs="https://ptable.com/wiki/compounds/A/Naproxen" title="Naproxen">Naproxen</a></li>
<li><a href="Oxaprozin.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxaprozin" title="Oxaprozin">Oxaprozin</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Oxicams</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width: auto;"><div style="padding:0em 0.25em">
<ul><li><a href="Meloxicam.htm" tppabs="https://ptable.com/wiki/compounds/A/Meloxicam" title="Meloxicam">Meloxicam</a></li>
<li><a href="Piroxicam.htm" tppabs="https://ptable.com/wiki/compounds/A/Piroxicam" title="Piroxicam">Piroxicam</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Acetates</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width: auto;"><div style="padding:0em 0.25em">
<ul><li><a href="Diclofenac.htm" tppabs="https://ptable.com/wiki/compounds/A/Diclofenac" title="Diclofenac">Diclofenac</a></li>
<li><a href="Indometacin.htm" tppabs="https://ptable.com/wiki/compounds/A/Indometacin" title="Indometacin">Indometacin</a></li>
<li><a href="Ketorolac.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketorolac" title="Ketorolac">Ketorolac</a></li>
<li><a href="Nabumetone.htm" tppabs="https://ptable.com/wiki/compounds/A/Nabumetone" title="Nabumetone">Nabumetone</a></li>
<li><a href="Sulindac.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulindac" title="Sulindac">Sulindac</a></li>
<li><a href="Tolmetin.htm" tppabs="https://ptable.com/wiki/compounds/A/Tolmetin" title="Tolmetin">Tolmetin</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">COX-2 inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width: auto;"><div style="padding:0em 0.25em">
<ul><li><a href="Celecoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Celecoxib" title="Celecoxib">Celecoxib</a></li>
<li><a href="Etoricoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Etoricoxib" title="Etoricoxib">Etoricoxib</a></li>
<li><a href="Lumiracoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lumiracoxib" title="Lumiracoxib">Lumiracoxib</a></li>
<li>Parecoxib</li>
<li><a href="Rofecoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Rofecoxib" title="Rofecoxib">Rofecoxib</a> <sup>‡</sup></li>
<li><a href="Valdecoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Valdecoxib" title="Valdecoxib">Valdecoxib</a> <sup>‡</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Fenamic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenamic_acid" title="Fenamic acid">Fenamates</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width: auto;"><div style="padding:0em 0.25em">
<ul><li><a href="Meclofenamic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Meclofenamic_acid" title="Meclofenamic acid">Meclofenamic acid</a></li>
<li><a href="Mefenamic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Mefenamic_acid" title="Mefenamic acid">Mefenamic acid</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Salicylic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicylic_acid" title="Salicylic acid">Salicylates</a></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width: auto;"><div style="padding:0em 0.25em">
<ul><li><a href="Aspirin.htm" tppabs="https://ptable.com/wiki/compounds/A/Aspirin" title="Aspirin">Aspirin (acetylsalicylic acid)</a><sup>#</sup> (+paracetamol/caffeine)</li>
<li>Benorylate</li>
<li><a href="Diflunisal.htm" tppabs="https://ptable.com/wiki/compounds/A/Diflunisal" title="Diflunisal">Diflunisal</a></li>
<li><a href="Ethenzamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethenzamide" title="Ethenzamide">Ethenzamide</a></li>
<li>Magnesium salicylate</li>
<li><a href="Salicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicin" title="Salicin">Salicin</a></li>
<li><a href="Salicylamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicylamide" title="Salicylamide">Salicylamide</a></li>
<li><a href="Salsalate.htm" tppabs="https://ptable.com/wiki/compounds/A/Salsalate" title="Salsalate">Salsalate</a></li>
<li>Wintergreen (<a href="Methyl_salicylate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyl_salicylate" title="Methyl salicylate">methyl salicylate</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Pyrazolones</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width: auto;"><div style="padding:0em 0.25em">
<ul><li><a href="Aminophenazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminophenazone" title="Aminophenazone">Aminophenazone</a><sup>‡</sup></li>
<li><a href="Ampyrone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ampyrone" title="Ampyrone">Ampyrone</a></li>
<li><a href="Metamizole.htm" tppabs="https://ptable.com/wiki/compounds/A/Metamizole" title="Metamizole">Metamizole (dipyrone)</a></li>
<li><a href="Nifenazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Nifenazone" title="Nifenazone">Nifenazone</a></li>
<li><a href="Phenazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenazone" title="Phenazone">Phenazone</a></li>
<li>Propyphenazone (+paracetamol/caffeine)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width: auto;"><div style="padding:0em 0.25em">
<ul><li><a href="Glafenine.htm" tppabs="https://ptable.com/wiki/compounds/A/Glafenine" title="Glafenine">Glafenine</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Cannabinoids</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Cannabidiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Cannabidiol" title="Cannabidiol">Cannabidiol</a></li>
<li>Cannabis</li>
<li><a href="Nabilone.htm" tppabs="https://ptable.com/wiki/compounds/A/Nabilone" title="Nabilone">Nabilone</a></li>
<li>Nabiximols</li>
<li><a href="Tetrahydrocannabinol.htm" tppabs="https://ptable.com/wiki/compounds/A/Tetrahydrocannabinol" title="Tetrahydrocannabinol">Tetrahydrocannabinol (dronabinol)</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Ion channel<br>modulators</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Calcium blockers</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width: auto;"><div style="padding:0em 0.25em">
<ul><li>Alcohol (ethanol)</li>
<li><a href="Gabapentin.htm" tppabs="https://ptable.com/wiki/compounds/A/Gabapentin" title="Gabapentin">Gabapentin</a></li>
<li>Gabapentin enacarbil</li>
<li>Mirogabalin</li>
<li><a href="Pregabalin.htm" tppabs="https://ptable.com/wiki/compounds/A/Pregabalin" title="Pregabalin">Pregabalin</a></li>
<li>Ziconotide</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Sodium blockers</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width: auto;"><div style="padding:0em 0.25em">
<ul><li><a href="Carbamazepine.htm" tppabs="https://ptable.com/wiki/compounds/A/Carbamazepine" title="Carbamazepine">Carbamazepine</a></li>
<li>Lacosamide</li>
<li>Local anesthetics (e.g., <a href="Cocaine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cocaine" title="Cocaine">cocaine</a>, <a href="Lidocaine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lidocaine" title="Lidocaine">lidocaine</a>)</li>
<li><a href="Mexiletine.htm" tppabs="https://ptable.com/wiki/compounds/A/Mexiletine" title="Mexiletine">Mexiletine</a></li>
<li>Nefopam</li>
<li>Tricyclic antidepressants (e.g., <a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">amitriptyline</a><sup>#</sup>)</li></ul>

<ul><li><i>Na<sub>v</sub>1.7/1.8-selective:</i> DSP-2230<sup>§</sup></li>
<li>Funapide<sup>§</sup></li>
<li>PF-05089771<sup>§</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Potassium openers</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width: auto;"><div style="padding:0em 0.25em">
<ul><li>Flupirtine<sup>‡</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Myorelaxants</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Carisoprodol.htm" tppabs="https://ptable.com/wiki/compounds/A/Carisoprodol" title="Carisoprodol">Carisoprodol</a></li>
<li><a href="Chlorzoxazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorzoxazone" title="Chlorzoxazone">Chlorzoxazone</a></li>
<li><a href="Cyclobenzaprine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclobenzaprine" title="Cyclobenzaprine">Cyclobenzaprine</a></li>
<li>Mephenoxalone</li>
<li><a href="Methocarbamol.htm" tppabs="https://ptable.com/wiki/compounds/A/Methocarbamol" title="Methocarbamol">Methocarbamol</a></li>
<li><a href="Orphenadrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Orphenadrine" title="Orphenadrine">Orphenadrine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Analgesic adjuvant</li>
<li>Analgecine</li>
<li><a href="Camphor.htm" tppabs="https://ptable.com/wiki/compounds/A/Camphor" title="Camphor">Camphor</a></li>
<li><a href="Capsaicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Capsaicin" title="Capsaicin">Capsaicin</a></li>
<li><a href="Clonidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Clonidine" title="Clonidine">Clonidine</a></li>
<li><a href="Ketamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketamine" title="Ketamine">Ketamine</a></li>
<li><a href="Menthol.htm" tppabs="https://ptable.com/wiki/compounds/A/Menthol" title="Menthol">Menthol</a></li>
<li><a href="Methoxyflurane.htm" tppabs="https://ptable.com/wiki/compounds/A/Methoxyflurane" title="Methoxyflurane">Methoxyflurane</a></li>
<li>Nefopam</li>
<li>Proglumide</li>
<li>Tricyclic antidepressants (e.g., <a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">amitriptyline</a><sup>#</sup>)</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd hlist" style="width:100%;padding:0px"><div style="padding:0em 0.25em"><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Prostanoid_signaling_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Prostanoid_signaling_modulators" style="font-size:114%;margin:0 4em">Prostanoid signaling modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Receptor<br><small>(ligands)</small></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>DP (D<sub>2</sub>)</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>DP<sub>1</sub></abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Agonists:</b> Prostaglandin D<sub>2</sub></li>
<li><a href="Treprostinil.htm" tppabs="https://ptable.com/wiki/compounds/A/Treprostinil" title="Treprostinil">Treprostinil</a></li></ul>

<ul><li><b>Antagonists:</b> <span class="new">Asapiprant</span></li>
<li>Laropiprant</li>
<li><span class="new">Vidupiprant</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>DP<sub>2</sub></abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Agonists:</b> <a href="Indometacin.htm" tppabs="https://ptable.com/wiki/compounds/A/Indometacin" title="Indometacin">Indometacin</a></li>
<li>Prostaglandin D<sub>2</sub></li></ul>

<ul><li><b>Antagonists:</b> <span class="new">ADC-3680</span></li>
<li><span class="new">AZD-1981</span></li>
<li><span class="new">Bay U3405</span></li>
<li>Fevipiprant</li>
<li><span class="new">MK-1029</span></li>
<li><span class="new">MK-7246</span></li>
<li><span class="new">QAV-680</span></li>
<li><a href="Ramatroban.htm" tppabs="https://ptable.com/wiki/compounds/A/Ramatroban" title="Ramatroban">Ramatroban</a></li>
<li>Setipiprant</li>
<li><span class="new">Timapiprant</span></li>
<li><span class="new">TM30089</span></li>
<li><span class="new">Vidupiprant</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>EP (E<sub>2</sub>)</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>EP<sub>1</sub></abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Agonists:</b> Beraprost</li>
<li>Enprostil</li>
<li><a href="Iloprost.htm" tppabs="https://ptable.com/wiki/compounds/A/Iloprost" title="Iloprost">Iloprost (ciloprost)</a></li>
<li><a href="Latanoprost.htm" tppabs="https://ptable.com/wiki/compounds/A/Latanoprost" title="Latanoprost">Latanoprost</a></li>
<li><a href="Lubiprostone.htm" tppabs="https://ptable.com/wiki/compounds/A/Lubiprostone" title="Lubiprostone">Lubiprostone</a></li>
<li><a href="Misoprostol.htm" tppabs="https://ptable.com/wiki/compounds/A/Misoprostol" title="Misoprostol">Misoprostol</a></li>
<li><a href="Prostaglandin_E1.htm" tppabs="https://ptable.com/wiki/compounds/A/Prostaglandin_E1" title="Prostaglandin E1">Prostaglandin E<sub>1</sub> (alprostadil)</a></li>
<li><a href="Prostaglandin_E2.htm" tppabs="https://ptable.com/wiki/compounds/A/Prostaglandin_E2" title="Prostaglandin E2">Prostaglandin E<sub>2</sub> (dinoprostone)</a></li>
<li><a href="Sulprostone.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulprostone" title="Sulprostone">Sulprostone</a></li></ul>

<ul><li><b>Antagonists:</b> <span class="new">AH-6809</span></li>
<li><span class="new">ONO-8130</span></li>
<li><span class="new">SC-19220</span></li>
<li><span class="new">SC-51089</span></li>
<li><span class="new">SC-51322</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>EP<sub>2</sub></abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Agonists:</b> <span class="new">Butaprost</span></li>
<li><a href="Misoprostol.htm" tppabs="https://ptable.com/wiki/compounds/A/Misoprostol" title="Misoprostol">Misoprostol</a></li>
<li><a href="Prostaglandin_E1.htm" tppabs="https://ptable.com/wiki/compounds/A/Prostaglandin_E1" title="Prostaglandin E1">Prostaglandin E<sub>1</sub> (alprostadil)</a></li>
<li><a href="Prostaglandin_E2.htm" tppabs="https://ptable.com/wiki/compounds/A/Prostaglandin_E2" title="Prostaglandin E2">Prostaglandin E<sub>2</sub> (dinoprostone)</a></li>
<li><a href="Treprostinil.htm" tppabs="https://ptable.com/wiki/compounds/A/Treprostinil" title="Treprostinil">Treprostinil</a></li></ul>

<ul><li><b>Antagonists:</b> <span class="new">AH-6809</span></li>
<li><span class="new">PF-04418948</span></li>
<li><span class="new">TG 4-155</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>EP<sub>3</sub></abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Agonists:</b> Beraprost</li>
<li><span class="new">Carbacyclin</span></li>
<li><span class="new">Cicaprost</span></li>
<li>Enprostil</li>
<li><a href="Iloprost.htm" tppabs="https://ptable.com/wiki/compounds/A/Iloprost" title="Iloprost">Iloprost (ciloprost)</a></li>
<li><span class="new">Isocarbacyclin</span></li>
<li><a href="Latanoprost.htm" tppabs="https://ptable.com/wiki/compounds/A/Latanoprost" title="Latanoprost">Latanoprost</a></li>
<li><a href="Misoprostol.htm" tppabs="https://ptable.com/wiki/compounds/A/Misoprostol" title="Misoprostol">Misoprostol</a></li>
<li>Prostaglandin D<sub>2</sub></li>
<li><a href="Prostaglandin_E1.htm" tppabs="https://ptable.com/wiki/compounds/A/Prostaglandin_E1" title="Prostaglandin E1">Prostaglandin E<sub>1</sub> (alprostadil)</a></li>
<li><a href="Prostaglandin_E2.htm" tppabs="https://ptable.com/wiki/compounds/A/Prostaglandin_E2" title="Prostaglandin E2">Prostaglandin E<sub>2</sub> (dinoprostone)</a></li>
<li><span class="new">Remiprostol</span></li>
<li><a href="Sulprostone.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulprostone" title="Sulprostone">Sulprostone</a></li></ul>

<ul><li><b>Antagonists:</b> <span class="new">L-798106</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>EP<sub>4</sub></abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Agonists:</b> <a href="Lubiprostone.htm" tppabs="https://ptable.com/wiki/compounds/A/Lubiprostone" title="Lubiprostone">Lubiprostone</a></li>
<li><a href="Misoprostol.htm" tppabs="https://ptable.com/wiki/compounds/A/Misoprostol" title="Misoprostol">Misoprostol</a></li>
<li><a href="Prostaglandin_E1.htm" tppabs="https://ptable.com/wiki/compounds/A/Prostaglandin_E1" title="Prostaglandin E1">Prostaglandin E<sub>1</sub> (alprostadil)</a></li>
<li><a href="Prostaglandin_E2.htm" tppabs="https://ptable.com/wiki/compounds/A/Prostaglandin_E2" title="Prostaglandin E2">Prostaglandin E<sub>2</sub> (dinoprostone)</a></li>
<li><span class="new">TCS-2510</span></li></ul>

<ul><li><b>Antagonists:</b> Grapiprant</li>
<li><span class="new">GW-627368</span></li>
<li><span class="new">L-161982</span></li>
<li><span class="new">ONO-AE3-208</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;">Unsorted</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Agonists:</b> <span class="new">16,16-Dimethyl Prostaglandin E<sub>2</sub></span></li>
<li><span class="new">Aganepag</span></li>
<li><a href="Carboprost.htm" tppabs="https://ptable.com/wiki/compounds/A/Carboprost" title="Carboprost">Carboprost</a></li>
<li><span class="new">Evatanepag</span></li>
<li>Gemeprost</li>
<li><span class="new">Nocloprost</span></li>
<li><span class="new">Omidenepag</span></li>
<li>Prostaglandin F<sub>2α</sub> (dinoprost)</li>
<li><span class="new">Simenepag</span></li>
<li><span class="new">Taprenepag</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>FP (F<sub>2α</sub>)</abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Agonists:</b> Alfaprostol</li>
<li><a href="Bimatoprost.htm" tppabs="https://ptable.com/wiki/compounds/A/Bimatoprost" title="Bimatoprost">Bimatoprost</a></li>
<li><a href="Carboprost.htm" tppabs="https://ptable.com/wiki/compounds/A/Carboprost" title="Carboprost">Carboprost</a></li>
<li>Cloprostenol</li>
<li>Enprostil</li>
<li><span class="new">Fluprostenol</span></li>
<li><a href="Latanoprost.htm" tppabs="https://ptable.com/wiki/compounds/A/Latanoprost" title="Latanoprost">Latanoprost</a></li>
<li>Prostaglandin D<sub>2</sub></li>
<li>Prostaglandin F<sub>2α</sub> (dinoprost)</li>
<li><span class="new">Sulotroban</span></li>
<li>Tafluprost</li>
<li><a href="Travoprost.htm" tppabs="https://ptable.com/wiki/compounds/A/Travoprost" title="Travoprost">Travoprost</a></li>
<li>Unoprostone</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>IP (I<sub>2</sub>)</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Agonists:</b> <span class="new">ACT-333679</span></li>
<li><span class="new">AFP-07</span></li>
<li>Beraprost</li>
<li><span class="new">BMY-45778</span></li>
<li><span class="new">Carbacyclin</span></li>
<li><span class="new">Cicaprost</span></li>
<li><a href="Iloprost.htm" tppabs="https://ptable.com/wiki/compounds/A/Iloprost" title="Iloprost">Iloprost (ciloprost)</a></li>
<li><span class="new">Isocarbacyclin</span></li>
<li><span class="new">MRE-269</span></li>
<li><span class="new">NS-304</span></li>
<li><a href="Prostacyclin.htm" tppabs="https://ptable.com/wiki/compounds/A/Prostacyclin" title="Prostacyclin">Prostacyclin (prostaglandin I<sub>2</sub>, epoprostenol)</a></li>
<li><a href="Prostaglandin_E1.htm" tppabs="https://ptable.com/wiki/compounds/A/Prostaglandin_E1" title="Prostaglandin E1">Prostaglandin E<sub>1</sub> (alprostadil)</a></li>
<li><span class="new">Ralinepag</span></li>
<li>Selexipag</li>
<li><span class="new">Taprostene</span></li>
<li><span class="new">TRA-418</span></li>
<li><a href="Treprostinil.htm" tppabs="https://ptable.com/wiki/compounds/A/Treprostinil" title="Treprostinil">Treprostinil</a></li></ul>

<ul><li><b>Antagonists:</b> <span class="new">RO1138452</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>TP (TX<sub>A2</sub>)</abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Agonists:</b> <span class="new">Carbocyclic thromboxane A<sub>2</sub></span></li>
<li><span class="new">I-BOP</span></li>
<li><a href="Thromboxane_A2.htm" tppabs="https://ptable.com/wiki/compounds/A/Thromboxane_A2" title="Thromboxane A2">Thromboxane A<sub>2</sub></a></li>
<li>U-46619</li>
<li><span class="new">Vapiprost</span></li></ul>

<ul><li><b>Antagonists:</b> 12-HETE</li>
<li><span class="new">13-APA</span></li>
<li><span class="new">AA-2414</span></li>
<li><a href="Argatroban.htm" tppabs="https://ptable.com/wiki/compounds/A/Argatroban" title="Argatroban">Argatroban</a></li>
<li><span class="new">Bay U3405</span></li>
<li><span class="new">BMS-180,291</span></li>
<li><span class="new">Daltroban</span></li>
<li><span class="new">Domitroban</span></li>
<li><span class="new">EP-045</span></li>
<li><span class="new">GR-32191</span></li>
<li><span class="new">ICI-185282</span></li>
<li><span class="new">ICI-192605</span></li>
<li>Ifetroban</li>
<li><span class="new">Imitrodast</span></li>
<li><span class="new">L-655240</span></li>
<li><span class="new">L-670596</span></li>
<li><span class="new">Linotroban</span></li>
<li><span class="new">Mipitroban</span></li>
<li><span class="new">ONO-3708</span></li>
<li><span class="new">ONO-11120</span></li>
<li><a href="Picotamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Picotamide" title="Picotamide">Picotamide</a></li>
<li><span class="new">Pinane thromboxane A<sub>2</sub></span></li>
<li><a href="Ramatroban.htm" tppabs="https://ptable.com/wiki/compounds/A/Ramatroban" title="Ramatroban">Ramatroban</a></li>
<li><span class="new">Ridogrel</span></li>
<li><span class="new">S-145</span></li>
<li><span class="new">Samixogrel</span></li>
<li>Seratrodast</li>
<li><span class="new">SQ-28,668</span></li>
<li><span class="new">SQ-29,548</span></li>
<li><span class="new">Sulotroban</span></li>
<li>Terbogrel</li>
<li>Terutroban</li>
<li><span class="new">TRA-418</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;">Unsorted</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">Arbaprostil</span></li>
<li><span class="new">Ataprost</span></li>
<li><span class="new">Ciprostene</span></li>
<li><span class="new">Clinprost</span></li>
<li><span class="new">Cobiprostone</span></li>
<li><span class="new">Delprostenate</span></li>
<li><span class="new">Deprostil</span></li>
<li><span class="new">Dimoxaprost</span></li>
<li><span class="new">Doxaprost</span></li>
<li><span class="new">Ecraprost</span></li>
<li><span class="new">Eganoprost</span></li>
<li><span class="new">Enisoprost</span></li>
<li><span class="new">Eptaloprost</span></li>
<li><span class="new">Esuberaprost</span></li>
<li><span class="new">Etiproston</span></li>
<li><span class="new">Fenprostalene</span></li>
<li><span class="new">Flunoprost</span></li>
<li><span class="new">Froxiprost</span></li>
<li><span class="new">Lanproston</span></li>
<li><span class="new">Limaprost</span></li>
<li><span class="new">Luprostiol</span></li>
<li><span class="new">Meteneprost</span></li>
<li><span class="new">Mexiprostil</span></li>
<li><span class="new">Naxaprostene</span></li>
<li><span class="new">Nileprost</span></li>
<li><span class="new">Nocloprost</span></li>
<li><span class="new">Ornoprostil</span></li>
<li><span class="new">Oxoprostol</span></li>
<li><span class="new">Penprostene</span></li>
<li><span class="new">Pimilprost</span></li>
<li><span class="new">Piriprost</span></li>
<li><span class="new">Posaraprost</span></li>
<li><span class="new">Prostalene</span></li>
<li><span class="new">Rioprostil</span></li>
<li><span class="new">Rivenprost</span></li>
<li><span class="new">Rosaprostol</span></li>
<li><span class="new">Spiriprostil</span></li>
<li><span class="new">Tiaprost</span></li>
<li><span class="new">Tilsuprost</span></li>
<li><span class="new">Tiprostanide</span></li>
<li><span class="new">Trimoprostil</span></li>
<li><span class="new">Viprostol</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Enzyme<br><small>(inhibitors)</small></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>COX</abbr><br>(<abbr>PTGS</abbr>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Salicylic acids:</i> Aloxiprin</li>
<li><a href="Aspirin.htm" tppabs="https://ptable.com/wiki/compounds/A/Aspirin" title="Aspirin">Aspirin (acetylsalicylic acid)</a></li>
<li>Benorilate (benorylate)</li>
<li>Carbasalate calcium</li>
<li><span class="new">Diflusinal</span></li>
<li>Dipyrocetyl</li>
<li><a href="Ethenzamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethenzamide" title="Ethenzamide">Ethenzamide</a></li>
<li>Guacetisal</li>
<li>Magnesium salicylate</li>
<li><a href="Mesalazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Mesalazine" title="Mesalazine">Mesalazine (5-aminosalicylic acid)</a></li>
<li><a href="Methyl_salicylate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyl_salicylate" title="Methyl salicylate">Methyl salicylate</a></li>
<li><span class="new">Salacetamide</span></li>
<li><a href="Salicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicin" title="Salicin">Salicin</a></li>
<li><a href="Salicylamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicylamide" title="Salicylamide">Salicylamide</a></li>
<li><a href="Salicylic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicylate" title="Salicylate" class="mw-redirect">Salicylate (salicylic acid)</a></li>
<li><a href="Salsalate.htm" tppabs="https://ptable.com/wiki/compounds/A/Salsalate" title="Salsalate">Salsalate</a></li>
<li><a href="Sodium_salicylate.htm" tppabs="https://ptable.com/wiki/compounds/A/Sodium_salicylate" title="Sodium salicylate">Sodium salicylate</a></li>
<li>Triflusal; <i>Acetic acids:</i> Aceclofenac</li>
<li><a href="Acemetacin.htm" tppabs="https://ptable.com/wiki/compounds/A/Acemetacin" title="Acemetacin">Acemetacin</a></li>
<li><span class="new">Aclofenac</span></li>
<li>Amfenac</li>
<li>Alclofenac</li>
<li>Bendazac</li>
<li><a href="Bromfenac.htm" tppabs="https://ptable.com/wiki/compounds/A/Bromfenac" title="Bromfenac">Bromfenac</a></li>
<li><a href="Bufexamac.htm" tppabs="https://ptable.com/wiki/compounds/A/Bufexamac" title="Bufexamac">Bufexamac</a></li>
<li>Bumadizone</li>
<li><span class="new">Cinmetacin</span></li>
<li><span class="new">Clometacin</span></li>
<li><a href="Diclofenac.htm" tppabs="https://ptable.com/wiki/compounds/A/Diclofenac" title="Diclofenac">Diclofenac</a></li>
<li>Difenpiramide</li>
<li><a href="Etodolac.htm" tppabs="https://ptable.com/wiki/compounds/A/Etodolac" title="Etodolac">Etodolac</a></li>
<li><a href="Felbinac.htm" tppabs="https://ptable.com/wiki/compounds/A/Felbinac" title="Felbinac">Felbinac</a></li>
<li>Fenclofenac</li>
<li>Fentiazac</li>
<li><span class="new">Glucametacin</span></li>
<li><a href="Indometacin.htm" tppabs="https://ptable.com/wiki/compounds/A/Indometacin" title="Indometacin">Indometacin (indomethacin)</a></li>
<li>Indometacin farnesil</li>
<li><a href="Ketorolac.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketorolac" title="Ketorolac">Ketorolac</a></li>
<li>Lonazolac</li>
<li>Mofezolac</li>
<li><a href="Nabumetone.htm" tppabs="https://ptable.com/wiki/compounds/A/Nabumetone" title="Nabumetone">Nabumetone</a></li>
<li>Oxametacin</li>
<li><span class="new">Oxindanac</span></li>
<li>Proglumetacin</li>
<li><a href="Sulindac.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulindac" title="Sulindac">Sulindac</a></li>
<li><span class="new">Sulindac sulfide</span></li>
<li><a href="Tolmetin.htm" tppabs="https://ptable.com/wiki/compounds/A/Tolmetin" title="Tolmetin">Tolmetin</a></li>
<li><span class="new">Zidometacin</span></li>
<li><a href="Zomepirac.htm" tppabs="https://ptable.com/wiki/compounds/A/Zomepirac" title="Zomepirac">Zomepirac</a>; <i>Propionic acids:</i> Alminoprofen</li>
<li><a href="Benoxaprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Benoxaprofen" title="Benoxaprofen">Benoxaprofen</a></li>
<li><span class="new">Bucloxic acid (blucloxate)</span></li>
<li><span class="new">Butibufen</span></li>
<li><a href="Carprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Carprofen" title="Carprofen">Carprofen</a></li>
<li>Dexibuprofen</li>
<li><span class="new">Dexindoprofen</span></li>
<li>Dexketoprofen</li>
<li><a href="Fenbufen.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenbufen" title="Fenbufen">Fenbufen</a></li>
<li><a href="Fenoprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenoprofen" title="Fenoprofen">Fenoprofen</a></li>
<li>Flunoxaprofen</li>
<li><a href="Flurbiprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Flurbiprofen" title="Flurbiprofen">Flurbiprofen</a></li>
<li><a href="Ibuprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibuprofen" title="Ibuprofen">Ibuprofen</a></li>
<li>Ibuproxam</li>
<li><a href="Indoprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Indoprofen" title="Indoprofen">Indoprofen</a></li>
<li><a href="Ketoprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoprofen" title="Ketoprofen">Ketoprofen</a></li>
<li>Loxoprofen</li>
<li>Miroprofen</li>
<li><a href="Naproxen.htm" tppabs="https://ptable.com/wiki/compounds/A/Naproxen" title="Naproxen">Naproxen</a></li>
<li>Naproxcinod</li>
<li><a href="Oxaprozin.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxaprozin" title="Oxaprozin">Oxaprozin</a></li>
<li>Pirprofen</li>
<li>Pranoprofen</li>
<li><a href="Suprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Suprofen" title="Suprofen">Suprofen</a></li>
<li>Tarenflurbil</li>
<li>Tepoxalin</li>
<li><a href="Tiaprofenic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Tiaprofenic_acid" title="Tiaprofenic acid">Tiaprofenic acid (tiaprofenate)</a></li>
<li>Vedaprofen; <i>Anthranilic acids (fenamic acids):</i> Etofenamic acid (etofenamate)</li>
<li><span class="new">Floctafenic acid (floctafenate)</span></li>
<li><a href="Flufenamic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Flufenamic_acid" title="Flufenamic acid">Flufenamic acid (flufenamate)</a></li>
<li><a href="Meclofenamic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Meclofenamic_acid" title="Meclofenamic acid">Meclofenamic acid (meclofenamate)</a></li>
<li><a href="Mefenamic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Mefenamic_acid" title="Mefenamic acid">Mefenamic acid (mefenamate)</a></li>
<li>Morniflumic acid (morniflumate)</li>
<li><a href="Niflumic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Niflumic_acid" title="Niflumic acid">Niflumic acid (niflumate)</a></li>
<li><span class="new">Talinflumic acid (talinflumate)</span></li>
<li><a href="Tolfenamic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Tolfenamic_acid" title="Tolfenamic acid">Tolfenamic acid (tolfenamate)</a>; <i>Pyrazolones:</i> Azapropazone</li>
<li><a href="Metamizole.htm" tppabs="https://ptable.com/wiki/compounds/A/Dipyrone" title="Dipyrone" class="mw-redirect">Dipyrone</a></li>
<li><a href="Isoniazid.htm" tppabs="https://ptable.com/wiki/compounds/A/Isopyrin" title="Isopyrin" class="mw-redirect">Isopyrin</a></li>
<li><a href="Oxyphenbutazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxyphenbutazone" title="Oxyphenbutazone">Oxyphenbutazone</a></li>
<li><a href="Phenylbutazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylbutazone" title="Phenylbutazone">Phenylbutazone</a>; <i>Enolic acids (oxicams):</i> Ampiroxicam</li>
<li>Droxicam</li>
<li><span class="new">Enolicam</span></li>
<li>Isoxicam</li>
<li>Lornoxicam</li>
<li><a href="Meloxicam.htm" tppabs="https://ptable.com/wiki/compounds/A/Meloxicam" title="Meloxicam">Meloxicam</a></li>
<li><a href="Piroxicam.htm" tppabs="https://ptable.com/wiki/compounds/A/Piroxicam" title="Piroxicam">Piroxicam</a></li>
<li><a href="Tenoxicam.htm" tppabs="https://ptable.com/wiki/compounds/A/Tenoxicam" title="Tenoxicam">Tenoxicam</a>; <i>4-Aminoquinolines:</i> <a href="Antrafenine.htm" tppabs="https://ptable.com/wiki/compounds/A/Antrafenine" title="Antrafenine">Antrafenine</a></li>
<li>Floctafenine</li>
<li><a href="Glafenine.htm" tppabs="https://ptable.com/wiki/compounds/A/Glafenine" title="Glafenine">Glafenine</a>; <i>Quinazolines:</i> Fluproquazone</li>
<li>Proquazone; <i>Aminonicotinic acids:</i> <span class="new">Clonixeril</span></li>
<li>Clonixin</li>
<li><a href="Flunixin.htm" tppabs="https://ptable.com/wiki/compounds/A/Flunixin" title="Flunixin">Flunixin</a>; <i>Sulfonanilides:</i> <span class="new">Flosulide</span></li>
<li><a href="Nimesulide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nimesulide" title="Nimesulide">Nimesulide</a>; <i>Aminophenols (anilines):</i> <a href="Acetanilide.htm" tppabs="https://ptable.com/wiki/compounds/A/Acetanilide" title="Acetanilide">Acetanilide</a></li>
<li>AM-404 (N-arachidonoylaminophenol)</li>
<li><a href="Bucetin.htm" tppabs="https://ptable.com/wiki/compounds/A/Bucetin" title="Bucetin">Bucetin</a></li>
<li><a href="Paracetamol.htm" tppabs="https://ptable.com/wiki/compounds/A/Paracetamol" title="Paracetamol">Paracetamol (acetaminophen)</a></li>
<li><span class="new">Parapropamol</span></li>
<li><a href="Phenacetin.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenacetin" title="Phenacetin">Phenacetin</a></li>
<li>Propacetamol; <i>Selective COX-2 inhibitors (coxibs):</i> Apricoxib</li>
<li><a href="Celecoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Celecoxib" title="Celecoxib">Celecoxib</a></li>
<li>Cimicoxib</li>
<li>Deracoxib</li>
<li><a href="Etoricoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Etoricoxib" title="Etoricoxib">Etoricoxib</a></li>
<li>Firocoxib</li>
<li><a href="Lumiracoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lumiracoxib" title="Lumiracoxib">Lumiracoxib</a></li>
<li>Mavacoxib</li>
<li>Parecoxib</li>
<li>Polmacoxib</li>
<li>Robenacoxib</li>
<li><a href="Rofecoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Rofecoxib" title="Rofecoxib">Rofecoxib</a></li>
<li>Tilmacoxib</li>
<li><a href="Valdecoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Valdecoxib" title="Valdecoxib">Valdecoxib</a>; <i>Others/unsorted:</i> Anitrazafen</li>
<li><span class="new">Clobuzarit</span></li>
<li><a href="Curcumin.htm" tppabs="https://ptable.com/wiki/compounds/A/Curcumin" title="Curcumin">Curcumin</a></li>
<li><span class="new">DuP-697</span></li>
<li><span class="new">FK-3311</span></li>
<li>Flumizole</li>
<li><span class="new">FR-122047</span></li>
<li><a href="Glimepiride.htm" tppabs="https://ptable.com/wiki/compounds/A/Glimepiride" title="Glimepiride">Glimepiride</a></li>
<li><a href="Hyperforin.htm" tppabs="https://ptable.com/wiki/compounds/A/Hyperforin" title="Hyperforin">Hyperforin</a></li>
<li><span class="new">Itazigrel</span></li>
<li><span class="new">L-655240</span></li>
<li><span class="new">L-670596</span></li>
<li>Licofelone</li>
<li>Menatetrenone (vitamin K<sub>2</sub>)</li>
<li><span class="new">NCX-466</span></li>
<li><span class="new">NCX-4040</span></li>
<li>NS-398</li>
<li>Pamicogrel</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Resveratrol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Resveratrol'" tppabs="https://ptable.com/wiki/compounds/A/Resveratrol" title="Resveratrol">Resveratrol</a></li>
<li><span class="new">Romazarit</span></li>
<li><a href="Rosmarinic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Rosmarinic_acid" title="Rosmarinic acid">Rosmarinic acid</a></li>
<li>Rutecarpine</li>
<li><span class="new">Satigrel</span></li>
<li><span class="new">SC-236</span></li>
<li><span class="new">SC-560</span></li>
<li><span class="new">SC-58125</span></li>
<li>Tenidap</li>
<li><span class="new">Tiflamizole</span></li>
<li><span class="new">Timegadine</span></li>
<li><span class="new">Trifenagrel</span></li>
<li><span class="new">Tropesin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>PGD<sub>2</sub>S</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Retinoids</li>
<li>Selenium (<a href="Selenium_tetrachloride.htm" tppabs="https://ptable.com/wiki/compounds/A/Selenium_tetrachloride" title="Selenium tetrachloride">selenium tetrachloride</a>, <a href="Sodium_selenite.htm" tppabs="https://ptable.com/wiki/compounds/A/Sodium_selenite" title="Sodium selenite">sodium selenite</a>, <a href="Selenium_disulfide.htm" tppabs="https://ptable.com/wiki/compounds/A/Selenium_disulfide" title="Selenium disulfide">selenium disulfide</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>PGES</abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em"><span class="new">HQL-79</span></div></td></tr><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>PGFS</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em"><a href="Bimatoprost.htm" tppabs="https://ptable.com/wiki/compounds/A/Bimatoprost" title="Bimatoprost">Bimatoprost</a></div></td></tr><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>PGI<sub>2</sub>S</abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em"><a href="Tranylcypromine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tranylcypromine" title="Tranylcypromine">Tranylcypromine</a></div></td></tr><tr><th scope="row" class="navbox-group" style="width:5em;;text-align:center;"><abbr>TXAS</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">Camonagrel</span></li>
<li><span class="new">Dazmegrel</span></li>
<li><a href="Dazoxiben.htm" tppabs="https://ptable.com/wiki/compounds/A/Dazoxiben" title="Dazoxiben">Dazoxiben</a></li>
<li><span class="new">Furegrelate</span></li>
<li><span class="new">Isbogrel</span></li>
<li><span class="new">Midazogrel</span></li>
<li><span class="new">Nafagrel</span></li>
<li><span class="new">Nicogrelate</span></li>
<li><a href="Ozagrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Ozagrel" title="Ozagrel">Ozagrel</a></li>
<li><a href="Picotamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Picotamide" title="Picotamide">Picotamide</a></li>
<li><span class="new">Pirmagrel</span></li>
<li><span class="new">Ridogrel</span></li>
<li><span class="new">Rolafagrel</span></li>
<li><span class="new">Samixogrel</span></li>
<li>Terbogrel</li>
<li><span class="new">U63557A</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Precursors:</b> <a href="Linoleic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Linoleic_acid" title="Linoleic acid">Linoleic acid</a></li>
<li><a href="Gamma-Linolenic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Gamma-Linolenic_acid" title="Gamma-Linolenic acid">γ-Linolenic acid (gamolenic acid)</a></li>
<li>Dihomo-γ-linolenic acid</li>
<li>Diacylglycerol</li>
<li><a href="Arachidonic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Arachidonic_acid" title="Arachidonic acid">Arachidonic acid</a></li>
<li>Prostaglandin G<sub>2</sub></li>
<li>Prostaglandin H<sub>2</sub></li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Leukotriene signaling modulators</i></dd></dl>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Merck_&amp;amp;_Co.,_Inc." style="padding:3px"><table class="nowraplinks hlist mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Merck_&amp;amp;_Co.,_Inc." style="font-size:114%;margin:0 4em">Merck &amp; Co., Inc.</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Corporate directors:</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Richard Clark</li>
<li>Johnnetta Cole</li>
<li>William Harrison</li>
<li><span class="new">William Kelley</span></li>
<li>Rochelle Lazarus</li>
<li>Thomas Shenk</li>
<li><span class="new">Anne Tatlock</span></li>
<li>Samuel Thier</li>
<li>Wendell Weeks</li>
<li><span class="new">Peter Wendell</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Products:</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Alendronic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Alendronic_acid" title="Alendronic acid">Alendronate</a></li>
<li><a href="Aprepitant.htm" tppabs="https://ptable.com/wiki/compounds/A/Aprepitant" title="Aprepitant">Aprepitant</a></li>
<li><a href="Ertapenem.htm" tppabs="https://ptable.com/wiki/compounds/A/Ertapenem" title="Ertapenem">Ertapenem</a></li>
<li><a href="Ezetimibe.htm" tppabs="https://ptable.com/wiki/compounds/A/Ezetimibe" title="Ezetimibe">Ezetimibe</a></li>
<li>Ezetimibe/simvastatin</li>
<li><a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">Finasteride</a></li>
<li>Fosaprepitant</li>
<li><a href="Indinavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Indinavir" title="Indinavir">Indinavir</a></li>
<li><a href="Losartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Losartan" title="Losartan">Losartan</a></li>
<li><a href="Lovastatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Lovastatin" title="Lovastatin">Lovastatin</a></li>
<li><a href="Montelukast.htm" tppabs="https://ptable.com/wiki/compounds/A/Montelukast" title="Montelukast">Montelukast</a></li>
<li>Omarigliptin</li>
<li>Raltegravir</li>
<li><a href="Rizatriptan.htm" tppabs="https://ptable.com/wiki/compounds/A/Rizatriptan" title="Rizatriptan">Rizatriptan</a></li>
<li><a href="Rofecoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Rofecoxib" title="Rofecoxib">Rofecoxib</a></li>
<li>rVSV-ZEBOV vaccine</li>
<li><a href="Simvastatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Simvastatin" title="Simvastatin">Simvastatin</a></li>
<li><a href="Sitagliptin.htm" tppabs="https://ptable.com/wiki/compounds/A/Sitagliptin" title="Sitagliptin">Sitagliptin</a></li>
<li><a href="Vorinostat.htm" tppabs="https://ptable.com/wiki/compounds/A/Vorinostat" title="Vorinostat">Vorinostat</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Publications:</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>The Merck Manuals
<ul><li><i>Index</i></li>
<li><i>Manual</i></li>
<li><i>Veterinary</i></li>
<li><i>Geriatrics</i></li></ul></li></ul>
</div></td></tr></tbody></table></div>






<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-07-08" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Rofecoxib&oldid=966656200  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Rofecoxib&oldid=966656200'" tppabs="https://en.wikipedia.org/wiki/?title=Rofecoxib&oldid=966656200">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>